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Abstract 
Lipoproteins of pathogenic Gram-negative bacteria are involved in different biological 
processes due to their highly immunogenic nature; and have proven to be good vaccine 
antigens. The lipoprotein translocation machinery of model organisms such as Escherichia 
coli is well characterized but unlikely E. coli, N. meningitidis displays many lipoproteins on its 
surface and recently an additional translocation component, Surface lipoprotein assembly 
modulators (Slam1 and Slam2), involved in the surface exposure of specific N. meningitidis 
lipoproteins, has been identified. Several aspects were investigated: first of all the sorting 
signals for Neisserial lipoproteins localization with a particular focus on the outer membrane 
crossing and surface localizations and the sorting differences of N. meningitidis with respect 
to the E. coli model were pointed out. The role of Slam1 for lipoproteins surface exposure was 
better characterized. Our results described a new role for Slam1 in outer membrane 
translocation of NHBA (Neisserial Heparin Binding Antigen) and Mip (Macrophage infectivity 
potentiator). fHbp as Slam1 substrate was confirmed but also a new role for Slam1 in fHbp 
expression stabilization was elucidated. Surface expression of N. meningitidis lipoproteins in 
the heterologous E. coli background was attempted, by taking advantage of Slam1 component 
which we clearly demonstrate to be necessary to actively translocate NHBA and fHbp on 
bacterial surface. Finally, the immunogenicity of OMVs with different lipoproteins surface 
display modulated by Slam1 expression was evaluated in homologous or heterologous 
systems. The immunogenicity studies suggested that Slam1 is able to drive bactericidal 
activity in N. meningitidis OMVs through modulating lipoprotein surface localization and 
furthermore other Slam-dependent bactericidal surface lipoproteins, different from fHbp and 
NHBA, might be present in N. meningitidis. We clearly demonstrated the importance of the co-
expression of surface lipoproteins with Slam1 for the correct display of antigens and we 
showed that, depending on the presence of Slam1, heterologous E. coli OMVs, enriched with 
N. meningitidis SLPs, elicit different antibody responses. 
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 Introduction 1
1.1 Gram negative bacteria 
Bacterial cell envelope is a complex multilayered structure that serves to protect bacteria 
from the environment. Cell envelopes classify bacteria into two major groups, Gram positive 
and Gram negative bacteria. Gram negative bacteria present a thin peptidoglycan cell wall 
and an external envelope membrane, called outer membrane, containing lipopolysaccharides. 
On the contrary, Gram positive bacteria have a thicker peptidoglycan cell wall and the outer 
membrane is missing [1]. Gram negative cell envelope is principally divided in three layers: 
the cytoplasmic or Inner Membrane (IM); the periplasm (an aqueous cellular compartment) 
and the Outer Membrane (OM) [1, 2]. Bacterial IM surrounds the cytoplasm and is made of a 
symmetrical phospholipid bilayer and membrane proteins that have key role in energy 
production/transduction, lipid biosynthesis, protein secretion and signal transduction [3]. 
The peptidoglycan (PG) is located in the periplasmic space and its principal roles are 
correlated to cell integrity and support for anchoring other cell envelope components [4]. 
Outside the periplasm, the aqueous layer between bacterial membranes, there is OM 
protecting bacteria from the environment [5]. The OM is an asymmetrical bilayer composed 
by phospholipids and lipopolysaccharides (LPS), in the inner and outer leaflet respectively [2, 
6]. 
In the OM two major classes of protein are found: Outer Membrane Proteins (OMP), 
characterized by transmembrane domains which span the membranes [7] and Lipoproteins 
(LP) anchored to outer membrane thanks to lipid chains at their N-terminal domain [8].  
1.1.1 Neisseria meningitidis  
Neisseria meningitidis is a Gram negative β-proteobacterium. An aerobic diplococcus, non-
motile and non-sporulating which can be either capsulated or un encapsulated; and humans 
are the unique reservoir of this bacterium.  
The N. meningitidis genome is around 2.1 Mb [9] and the species is classified into 13 
serogroups based on the immunogenicity and the structure of the polysaccharide capsule 
[10], Among these groups only six (A, B, C, W-135, X, Y) cause life-threatening disease [10]. N. 
meningitidis is usually carried asymptomatically at the level of the mucosal epithelium of the 
respiratory tract and spreads by respiratory droplets [11]. Menigoccoccus, infrequently, can 
cross the epithelial barrier resulting in access to the bloodstream and fulminant sepsis or 
focal infections such as meningitis [12]. The switch from the commensal to pathogenic state is 
poorly understood, but thanks to N. meningitidis genome plasticity, it is able to evolve 
strategies to efficiently survive in both situations [13].  
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Different virulence factors are expressed by N. meningitidis and are mainly involved in host-
pathogen interactions, immune evasion and nutrients uptake [13]. For example, the 
polysaccharide capsule represents a barrier against the host immune system [14] while LPS, 
referred to as lipooligosaccharide (LOS) due to the lack of an O-antigen, is required for 
resistance of N. meningitidis to serum complement [15]. Other virulence factors such as pili, 
consisting of protein subunits that protrude from the bacterial capsule; and Opa and Opc, 
which are OM-associated transmembrane proteins, important in adhesion and host cell 
interaction [16, 17]. Finally, lipoproteins involved in adhesion, immune evasion and iron 
acquisition [18-20] play also a key role in meningococcal pathogenesis.  
 
1.2 Lipoprotein translocation mechanism 
1.2.1 Lipoproteins 
Lipoproteins are molecules both present in Gram-positive and -negative bacteria involved in 
various processes ranging from outer membrane stabilization, and interaction with host cells 
to nutrient acquisition [18-24]. Many lipoproteins from pathogenic bacteria, have been 
selected as vaccine antigens because of their ability to stimulate the immune system, both via 
the acquired and innate responses [25-27]. Lipoproteins (Figure 1) are associated to 
membranes thanks to a characteristic lipid moiety at the N-terminal which facilitates the 
anchoring of the hydrophilic domain to the membrane, allowing the protein to function in an 
aqueous environment [28].  
 
 
Lipoproteins’ signal peptide has the peculiarity of a conserved motif at the C-terminus called 
the lipobox, composed by four amino acids L(A/S)(G/A)C, and the cysteine is the first amino 
acid of the mature lipoprotein where diacylglycerol and fatty acyl chains are added [29, 30] 
Looking at the bacteria genome for the presence of coding sequences including the 
characteristic lipobox motif, it is evident that most bacteria usually encode approximately 
100 to 200 putative lipoproteins [31].  
Figure 1 Schematic representation of lipoproteins. Lipobox motif with the conserved Cysteine is 
highlighted in red. Arrow indicated the cleavage site of the signal peptide. 
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Lipoproteins are synthetized in the cytosol as a precursor and translocated across the inner 
membrane via the Sec or Tat machinery [32, 33]. As immature proteins, with the type II signal 
peptides [34], they reach the outer leaflet of the inner membrane and undergo sequential 
reactions of maturation including lipid modification and signal peptide cleavage.  
Three different enzymes (Lgt, SpII and Lnt) are involved in these post-translational 
modifications and they appear to be essential in most of the Gram-negative bacteria (Figure 
2) [35, 36].  
 
 
Upon membrane insertion of the immature lipoprotein, prolipoprotein, Lgt 
(diacylglyceryltransferase) transfers the diacylglceryl group, from the phosphatidylglycerol 
to the sulfidryl group of the conserved cysteine [37]. This intermediate is then recognized by 
SpII (Signal peptidase II) which cleaves the signal peptide leaving the acylate cysteine as the 
first amino acid of the mature lipoprotein. Lnt (N-acyltrasferase) is the last enzyme involved 
and is able to attach an acyl group to the N-terminal residue of the cysteine creating the 
mature triacylated lipoprotein [30, 38]. 
1.2.2 Surface exposed lipoproteins 
Lipoproteins are usually found to be anchored to the membrane but facing the periplasm 
however in the past years some lipoproteins were found to be displayed on the outer leaflet 
of the outer membrane. This new class of lipoproteins called surface lipoproteins (SLP) is 
highly heterogeneous and no common features were identified to date, suggesting the 
existence of many different ways by which lipoproteins might reach cell surface and 
consequently, the presence of various mechanisms for lipoprotein translocation among 
bacteria [39, 40].  
Figure 2 Lipoproteins maturation process. Prolipoprotein cross the inner membrane with Sec machinery. 
Lgt enzyme catalyzes transfer of a diacylglyceryl group on the cysteine; SpII cleaves the signal peptide and  
Lnt adds a third acyl group on the cysteine (adapted from Wilson et al. 2016) 
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As example PulA of K. pneumoniae is a lipoprotein found either secreted or anchored to the 
outer leaflet of the outer membrane. PulA reaches the surface thanks to the type II secretion 
system, that acquires its substrate from the IM [41]. Autotransporters use Type Va secretion 
system for passing the outer membrane. Their N-terminal domain can reach the bacterial 
surface thanks to the C-terminal translocator domain and lipidated passenger domain is then 
anchored at the outer leaflet of the OM [42-44]. B. burgdorferi, member of the spirochete 
family, has the most abundant number of surface lipoproteins (SLPs) [45]. These bacteria 
exhibit an incomplete Lol system and Schulez et al. suggested that lipoproteins are 
translocated onto the surface by default and outer membrane proteins can help in the 
translocation to the surface [46, 47]. It was also described that in E. coli RcsF shows a 
transmembrane topology with the C-terminal domain that remains in the periplasm, while its 
lipidated N-terminal domain is displayed on the outer leaflet of the OM thanks to the 
interaction with the Bam complex [48]. In summary, surface lipoproteins show the necessity 
to translocate across the OM and, as described above, some of them require OMP to cross the 
phospolipid bilayer.  
In N. meningitidis, different SLPs were found on the bacterial surface [49] and most of them 
are virulence factors. Well known lipoproteins displayed on the surface are fHbp (factor H 
binding protein) [19], NHBA (Neisserial Heparin Binding Antigen) [50], TbpB (Transferrin 
Binding Protein B ), LpbB (Lactoferrin Binding Protein B), HpuA (hemoglobin-haptoglobin 
utilization protein A) [51-53] and NalP (Neisserial autotransporter lipoprotein) [42]. With 
the exception of NalP that, as mentioned above is an autotrasporter, all the other SLPs require 
the support of outer membrane proteins for their surface localization.  
1.2.3 Lipoproteins Outer membrane localization system 
Mature lipoproteins are localized either in the inner or the outer membrane depending on 
sorting signals. In E. coli, and in general in the Enterobacteriacee family, the signal for IM 
retention is the presence of an aspartate in position +2 after the lipidated cysteine (Figure 
3.A) [54, 55]. This signal is not conserved across bacterial families and for example in P. 
aeruginosa the amino acid in position +3 and +4 play a role in the localization [56]. 
In E. coli, and in general in all Gram negative bacteria, mature lipoproteins are translocated to 
the OM by the Lol (Lipoprotein outer membrane localization) pathway [57] (Figure 3.A). 
Even if the signal for the correct localization of the lipoproteins is not completely elucidated, 
the Lol pathway is highly conserved among bacteria. In N. meningitidis, homologous proteins 
to the E. coli Lol system were identified [58] but, contrarily to E. coli, lipoproteins can reach 
bacteria surface thanks the newly identified translocator component Slam (Surface 
lipoprotein assembly modulator) [59] (Figure 3.B). The signals required for lipoproteins 
localization in N. meningitidis are yet to be understood.  
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In general the Lol system is composed by three different components: an ABC transporter 
(Lol CDE), a chaperonine (LolA) and a lipoprotein (LolB) [30]. 
The ABC transporter LolCDE complex is involved in the first step of the translocation process, 
and is present at the level of the inner membrane. In E. coli, LolC and LolE are integral 
membrane proteins, encoded by two different genes with high levels of homology and form a 
heterodimer. On the contrary, in N. meningitidis, only one gene encoded for the LolC/E gene 
homolog was identified, therefore the complex is composed by a LolC/E homodimer instead a 
LolC/LolE dimer [58]. This complex captures the lipoprotein from the IM through 
conformational changes. The complex LolCE-lipoprotein interacts with LolD, which 
hydrolyzes ATP to support the transfer of the lipoprotein from LolCE to the hydrophobic 
cavity of the chaperonin LolA and the consequent release in the periplasm of the 
LolA:Lipoprotein complex [60]. 
LolA and LolB show a similar structure, they are folded in an incomplete β-barrel which 
forms a hydrophobic cavity that provides a binding site for lipoproteins acyl chains [61], this 
symmetrical structure of LolA and LolB are important for transferred lipoprotein. When the 
LolA:Lipoprotein complex reaches the OM the acyl chains are then transferred to LolB which 
mediates the anchoring of the lipoprotein to the inner leaflet of the OM [62].  
 
 
 
  
A) 
Figure 3 Lipoprotein outer membrane mechanisms. Schematic representation of the differences between 
E. coli and N. meningitidis. 
B) 
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1.2.4 Surface Lipoprotein assembly modulator family 
Recently Hooda et al. have identified the new class of translocator component localized in the 
outer membrane involved in the localization of specific meningococcal SLPs [59] (Figure 
3.B). This new class of translocator component, the Slam (Surface lipoprotein assembly 
modulator) family, was identified throughout the Proteobacteria phylum and in some 
bacteria more than one Slam component were identified [63].  
Slam proteins are characterized by the presence C- terminal domain folded with β-strands in 
a β-barrel which spans the outer membrane and an N-terminal soluble domain containing 
TPR-repeats [59]. Often, Slam genes are localized close to lipoprotein genes. In N. meningitidis 
two different Slam were identified, Slam1 and Slam2 which show different specificity for 
lipoprotein translocation. Slam2 gene was found in proximity of HpuA gene, and further 
analysis revealed that Slam2 specifically translocates only HpuA on bacterial surface. 
Conversely, no lipoproteins were found in proximity of the Slam1 gene and many different 
substrates were identified. fHbp, TbpB and LpbB were specifically translocated on bacterial 
surface by Slam1 [59]. 
All the Slam family substrates identified so far are characterized by a common predicted 
structural folding consisting of a β-barrel domain and a β-rich handle domain [63]. 
 
1.3 Outer membrane vesicles 
Outer membrane vesicles (OMVs) are small spherical blebs naturally released by Gram-
negative bacteria, both pathogenic and commensal [64]. Generally described as vesicles with 
20-250 nm diameters, OMVs are produced during active growth. Their generation depends 
on the detachment of the OM from the underlying peptidoglycan structure, so that a portion 
of OM can extrude and finally be released from the cell. Being liberated from the outer 
membrane they are mainly formed by Outer Membrane Proteins (OMPs), lipopolysaccharide 
(LPS), phospholipids, periplasmic proteins and lipoproteins and only few cytoplasmic 
proteins were found [65, 66] (Figure 4), suggesting that OMVs biogenesis is a deliberate 
process rather than a stochastic event due to cell lysis [67].  
OMV production was reported both in vitro as well as in in vivo conditions [68, 69] and, in the 
past ten years, the biological role of OMVs was deeply investigated. Yet, for the moment, there 
is not a single picture that explains all the functional or mechanistic aspects of OMVs 
production. 
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OMVs are indispensable for bacteria and contribute either to bacterial survival or virulence. 
In the literature, various roles of OMVs in bacterial physiology and pathogenesis were 
reported [70]. They can be utilized from the bacterium to improve bacterial survival or to 
induce changes in the environment, including the host and the surrounding bacterial 
community.  
It is reported that under stress conditions, bacteria increase OMVs production and this 
mechanisms could help preventing the accumulation of misfolded proteins and their toxic 
effect [71]. OMVs contribute to innate bacterial defenses conferring protection against 
antibiotics and antimicrobial peptides [72]. OMVs are also identified so far as important 
delivery systems. We can list different types of molecules found on OMVs ranging from 
proteins to saccharides and nucleic acids [67, 73, 74]. Last but not least, OMVs released from 
pathogenic bacteria play important roles in the delivery of toxins and virulence factors and 
can also be involved in nutrient acquisitions and interaction with host cells [75, 76]. They are 
often considered a non-replicative representation of the parent bacterium. OMVs contain 
innate immuno-stimulatory properties able to facilitate activation of the immune system [77], 
and OMVs purified from several pathogens are able to induce protective immune responses 
against the pathogen from which they are purified[74, 76-79]. Furthermore, thanks to the 
ability to genetically engineer the OMVs-producing bacteria, this system proves to be 
versatile and can be exploited as a vaccine platform [80, 81].   
Figure 4 Model of Outer Membrane Vesicles (OMV) biogenesis. Outer membrane protrusion liberates the 
membrane from the underlying peptidoglycan layer and OMVs vesicles are release. Vesicles are 
proteoliposomes consisting of OM phospholipids and LPS, a subset of OM proteins and periplasmic 
(luminal) proteins. (LPS) Lipopolysaccharide; (Pp) periplasm; (OM) outer membrane; (IM) inner 
membrane. 
13 
 
 Aims 2
The main aim of this project is the characterization of N. meningitidis lipoprotein 
translocation system; with a particular focus on the outer membrane crossing and surface 
localization.  
 
In particular this work is based on the investigation of different topics: 
 
 Investigation of Neisserial lipoproteins distribution to identify possible sorting 
signals involved in lipoproteins localization.  
 Investigation of whether different lipoproteins can be translocated onto the Neisserial 
surface in a Slam1-dependent manner.  
 Evaluation of the immunogenicity in mice of OMVs obtained by modulating SLPs 
surface exposure in N. meningitidis.  
 Employment of E. coli as a heterologous system to express Neisserial immunogenic 
lipoproteins on the surface and evaluation of the ability of the resulting OMVs to 
induce a functional immune response. 
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Chapter One  
 
Slam1 translocates NHBA and Mip 
onto the meningococcal surface 
and influences OMV 
immunogenicity 
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The Neisseria genus contains N. meningitidis and N. gonorrhoeae , two strictly human 
pathogens present at level of mucosal surface such as the nasopharynx or genital epithelium 
[82]. In N. meningitidis and N. gonorrhoeae eight different lipoproteins were experimentally 
identified on the bacterial surface [49] and most of them are virulence factors, including fHbp 
(only surface exposed in meningococcus) [19], NHBA [50], TbpB , LpbB , Mip (Macrophage 
infectivity potentiator) [83] and HpuA [51-53]. Many of these SLPs, except for Mip, show a 
conserved β-barrel domain in the C-terminal portion, suggesting the presence of a common 
ancestor [84-86]. Recently a class of OMP, named Surface lipoprotein assembly modulator 
(Slam), was identified as essential for the surface localization of specific SLPs in N. 
meningitidis [59]. This new class of translocator was identified throughout the Proteobacteria 
phylum and in some of them more than one Slam were identified using Slam1 sequence from 
MC58 as query [63] .  
In N. meningitidis two different Slam were identified Slam1 which can translocate different 
SLPs as fHbp TbpB and LpbB on bacterial surface; and Slam2 which specifically translocate 
Neisserial HpuA on bacteria surface [59]. 
One of the aims of this work was to elucidate sorting signals for lipoprotein localization in N. 
meningitidis. To this end Neisseria lipoproteins were predicted in MC58 N. meningitidis strain 
and analyzed in order to identify signals for IM/OM localization or necessary for surface 
translocation. Secondly, we investigated if other meningococcal SLPs are translocated by 
Slam1 onto the bacterial surface and finally we evaluate, how different SLPs exposure, 
through Slam1 modulation, can affect immunogenicity of meningococcal OMVs in mice.  
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 Results 3
3.1 Neisseria species require different signals, compared to E. coli, for 
the correct lipoprotein distribution 
In other bacterial species lipoproteins are localized either to the inner membrane or the outer 
membrane depending on the presence of signals within the amino acid sequence [29, 56].  
In particularly E. coli signals involved in correct localization of lipoproteins have been deeply 
investigated in the past. Based on the presence of the lipobox motif, 2% of the coding 
sequence are predicted to be lipoproteins in K-12 E. coli reference strain [31]. An aspartate in 
position +2 after the lipidated cysteine was found to be responsible for the retention to the 
IM [87] in E. coli, the retention signals were further investigates and the “+2 rule” was 
confirmed as guide principle although is not universal in Gram negative bacteria [57].  
In N. meningitidis signals involved in lipoproteins localization were not yet investigated 
therefore to elucidate possible signals we performed a systematic analysis of all predicted 
lipoproteins within the MC58 Neisserial genome by using Lipo P, which is an online server 
that produces a prediction of lipoproteins based on their specific signal peptide sequence and 
can discriminate it from other signal peptides [34]. In N. meningitidis the number of 
lipoproteins found (Table 1), represents 3.3 % of all predicted ORFs which is a higher 
percentage of lipoprotein content in this species as compared to E. coli in which the 
percentage is around 2% either pathogenic (EHEC 0157:H7 1,84%) and non-pathogenic (K-
12 2.02 %) strains [31]. 
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Table 1: List of predicted lipoproteins In table the predicted list of lipoproteins with the amino acid sequences long more than 100 amino acids 
 
 GENE number Gene Product   GENE number Gene Product 
1 NMB0032 - hypothetical protein  34 NMB1279 - membrane-bound lytic murein transglycosylase B 
2 NMB0033 Mlt-A membrane-bound lytic murein transglycosylase A  35 NMB1309 - fimbrial biogenesis and twitching motility protein 
3 NMB0035 - hypothetical protein  36 NMB1335 creA creA protein 
4 NMB0044 pilB trifunctional thioredoxin/methionine sulfoxide reductase A/B protein  37 NMB1369 - hypothetical protein 
5 NMB0071 ctrA capsule polysaccharide export outer membrane protein  38 NMB1433 - hypothetical protein 
6 NMB0086 - hypothetical protein  39 NMB1434 plpD phopholipase D-family protein 
7 NMB0204   lipoprotein, putative smpA  40 NMB1468 - hypothetical protein 
8 NMB0278 dsbA-1 thiol:disulfide interchange protein DsbA  41 NMB1470 - hypothetical protein 
9 NMB0294 dsbA-2 thiol:disulfide interchange protein DsbA  42 NMB1483 NlpD lipoprotein NlpD 
10 NMB0375 mafA-1 mafA protein  43 NMB1533 - outer membrane protein 
11 NMB0460 tbp2 transferrin-binding protein B  44 NMB1541 lbpB lactoferrin-binding protein 
12 NMB0532 htrA protease Do  45 NMB1567 mip macrophage infectivity potentiator 
13 NMB0550 dsbC thiol:disulfide interchange protein DsbC  46 NMB1578 - hypothetical protein 
14 NMB0563 apbE thiamine biosynthesis lipoprotein ApbE  47 NMB1592 - lipoprotein 
15 NMB0623 potD-2 spermidine/putrescine ABC transporter substrate-binding protein  48 NMB1594 potD-3 spermidine/putrescine ABC transporter substrate-binding protein 
16 NMB0652 mafA-2 mafA protein  49 NMB1612 - amino acid ABC transporter substrate-binding protein 
17 NMB0703 comL competence lipoprotein  50 NMB1620 - hypothetical protein 
18 NMB0707 - rare lipoprotein B  51 NMB1623 pan1 major anaerobically induced outer membrane protein 
19 NMB0787 - amino acid ABC transporter substrate-binding protein  52 NMB1674 - GDSL lipase 
20 NMB0841 - hypothetical protein  53 NMB1714 mtrE multidrug efflux pump channel protein 
21 NMB0873 lolB outer membrane lipoprotein LolB  54 NMB1716 mtrC membrane fusion protein 
22 NMB0923 - cytochrome c  55 NMB1811 pilP pilP protein 
23 NMB1010 - hypothetical protein  56 NMB1870 fHbp hypothetical protein 
24 NMB1017 sbp sulfate ABC transporter substrate-binding protein  57 NMB1880 - ABC transporter substrate-binding protein 
25 NMB1047 - hypothetical protein  58 NMB1898 mlp lipoprotein 
26 NMB1107 - hypothetical protein  59 NMB1946 - outer membrane lipoprotein 
27 NMB1124/1162 - hypothetical protein  60 NMB1949 - soluble lytic murein transglycosylase 
28 NMB1125/1163 - hypothetical protein  61 NMB1969 NalP serotype-1-specific antigen 
29 NMB1126/1164 - hypothetical protein  62 NMB1989 - iron ABC transporter substrate-binding protein 
30 NMB1162/1124 - hypothetical protein  63 NMB2091 - hemolysin 
31 NMB1163/1125 - hypothetical protein  64 NMB2132 NHBA transferrin-binding protein-like protein 
32 NMB1164/1126 - hypothetical protein  65 NMB2139 - hypothetical protein 
33 NMB1213 - lipoprotein      
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In order to see if any specific amino acid motifs emerged the first 50 amino acids, including the 
signal peptide, from the sequences in the predicted list of lipoproteins were aligned around the 
conserved cysteine (+1) of the lipobox and a consensus sequence was visualized using WebLogo 
(Figure 5) [88]. As expected, the Leucine (L) and the Cysteine (C) of the lipobox motif were 
conserved in all sequences while, interestingly, looking at the residue in position +2 Glycine (G) 
and Serine (S) were the most abundant residues among the analyzed sequences.  
 
 
For some lipoproteins the localization was known to be in the outer membrane, but for the 
major part of the lipoproteins the localization was not described in literature. To further 
understand the possible distribution of lipoproteins between the inner or outer membranes, we 
combined the proteomic analysis available in the literature for purified OM and spontaneously 
released OM blebs [66]. Based on their presence in OMVs or OM preparations, we presumed that 
these lipoproteins were anchored to the OM and hence, by exclusion, we assumed other 
lipoproteins were retained in the IM. As is shown in Figure 6, the majority (64%) of the 
lipoproteins could be found in the OM preparations. 
 
 
 
  
 
Figure 5 Lipoproteins alignment. A) The first 50 amino acids of N. meningitidis predicted lipoprotein were 
aligned and a LOGO was generated by using WebLogo. Sequence conservation, frequency and characteristics 
of each amino acid (aa) at each position are shown. Colors are representative of the aa characteristics: Green, 
polar (G, S, T, Y, C, Q, N); Blue ,basic (K, R, H); Red, acid (D, E); Black, hydrophobic (A, V, L, I, P, W, F, M). 
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Looking at the aminoacid in position +2 it appears that the “+2 rule” is not applicable in N. 
meningitidis, as an aspartate (D) was present at the +2 position only in two lipoprotein 
sequences and they were detected either in the IM or OM. Secondly we were not able to assign 
and correlate a specific aminoacid in position +2 with the localization in the IM or OM. All the 
amino acids in position +2 were found both in the IM and OM, suggesting that other signals in 
other position of the sequences were involved in the retention to the inner membrane. 
 
 
      
AA in position +2 
Number of 
proteins 
OMV 
positive 
IM positive 
Glycine 26 14 12 
Serine 15 10 5 
Alanine 7 5 2 
Glutamine 6 4 2 
Threonine 3 3 0 
Aspartate 2 1 1 
Leucine 2 2 0 
Asparagine 1 1 0 
Isoleucine 1 1 0 
lysine 1 1 
 Valine 1 1 
 TOT 65 42 23 
     
 
 
  
Figure 6: Lipoproteins distribution in N. meningitidis. Lipoprotein distribution based on proteomic data were 
summarized in the pie chart. In the table is reported the frequency of the amino acid in position +2 and relative 
distribution among the inner membrane (IM) or outer membrane as OMVs positive (OMVs).  
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3.2  The C- Term β-barrel domain is well conserved among N. meningitidis 
SLPs, and seems to be important for the surface localization  
As mentioned above in the introduction, in N. meningitidis some lipoproteins are known to be 
surface exposed, including HpuA, TbpB, LpbB, fHbp and NHBA. Despite the low sequence 
similarity, these SLPs show conserved structure at the C-terminal, which is stably folded in an 8-
stranded β-barrel domain. Since the MC58 N. meningitidis strain does not express HpuA only 4 
SLPs structures were reported (Figure 7).   
 
 
To investigate if this recurrent β-barrel domain was important for the surface localization we 
used NHBA as a model to study the surface translocation. It has been described that NHBA 
contains two cleavage sites upstream of the C-terminal domain and as such this protein is 
naturally present on the surface as two truncated forms lacking the C-terminus [50]. We 
generated a set of recombinant strains in which the genes encoding either the wildtype (WT) 
protein or two truncated forms of NHBA lacking the C-terminal domain (S1TGA1 and S2TGA2), 
generated by mutagenesis of the serine cleavage sites with a stop codon (Figure 8.A) were 
expressed under the control of an IPTG-inducible promoter, as described in the material and 
method session (7.2.1). These constructs were then inserted into the chromosome of the MC58 
ΔNHBA background by ex-locus complementation. Bacteria were grown in GC medium with 
0,1mM IPTG until exponential phase, then bacterial total lysates and fixed bacteria were 
collected and analyzed for NHBA expression and surface localization by Western blot and FACS, 
respectively (Figure 8.B and C).  
Figure 7 Structures of known MC58 SLPs. Modeled structures of four N. meningitidis SLPs were represented. 
Using Pymol program, β- barrel domains were highlighted in blue. TbpB and LpbB possess two copies of β-
barrel domains, but for LpbB only the C-lobe was reported. 
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Western blot analysis confirmed the expression of wild-type gene as the full length protein 
(higher band) and the two cleaved forms (lower bands). Each truncated NHBA gene was stably 
expressed and detectable (Figure 8.B). In the S1TGA1 truncated form only one band, 
corresponding to the lower N-terminal truncated band in the WT was visible. In the S2TGA2 
truncated form the major band corresponds to the longer N-term truncated form and a less 
abundant band corresponding to the short form were visible. 
NHBA surface localization was analyzed by FACS (Figure 8.C) using polyclonal α-NHBA sera. No 
NHBA was detectable on the surface in both strains expressing the truncated forms, while WT 
NHBA was clearly surface exposed in MC58 WT strain. This suggests that in the absence of the C-
terminal β-barrel, the N-terminal domains are expressed but not translocated to the surface. 
 
 
Figure 8. The C-terminal of NHBA is important for surface localization. A) Schematic representation NHBA 
truncated forms cloned and expressed in N. meningitidis MC58 ΔNHBA strain. B) Western blot analysis. Total 
lysates collected were loaded on a SDS gel and transferred on nitrocellulose membrane, stained with 
polyclonal sera α-NHBA (1:2000). Arrows highlighted the different NHBA forms. C) FACS analysis on fixed 
bacteria, they were first stained with α-NHBA polyclonal sera (1:800) and subsequently with FITC-labeled 
anti-mouse secondary antibodies (1:1000). * aspecific band. 
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To further investigate the role of the C-terminal domain in surface translocation; we generated a 
fusion protein in which the β-barrel portion of NHBA was substituted with the β-barrel of fHbp 
and we tested if the structure was enough to restore the delivery of N-terminal portion of NHBA 
onto the bacterial surface. A second fusion protein in which the N-terminal portion of fHbp was 
fused with the C-terminal portion of NHBA was also generated (Figure 9.A). These fusion 
constructs were cloned under the control of an IPTG inducible promoter and incorporated into 
the chromosome of MC58 ΔNHBA ΔfHbp background by ex-locus complementation. Bacterial 
strains were grown until exponential phase in GC media in the presence of 0,1mM of IPTG, fixed 
bacteria and total lysates were collected, and protein expression and surface localization were 
analyzed by Western Blot and FACS respectively.  
 
Total cell extracts of MC58 WT and the recombinant strains expressing the f-N and N-f fusion 
proteins were analyzed by WB and samples were analyzed either with α-fHbp and α-NHBA 
polyclonal sera (Figure 9.B and C). Western blot confirmed the expression of both chimeric 
constructs. Strangely the f-N construct was poorly recognized by Western Blot with anti-NHBA 
antisera, and reasons for this were not further explored, however, both chimeric proteins were 
successfully detected by anti-fHbp antisera and it was possible to appreciate the differences in 
the molecular weight between the WT, the f-N and the N-f protein due to the different N-
terminal portions exchanged among fHbp and NHBA.  
Surface exposure of these fusion proteins was analyzed by FACS (Figure 10). 
Figure 9. N-f and f-N fusion proteins were stably expressed. A) Schematic representation of the cloned fusion 
proteins. N-f fusion (N-term NHBA with the C-term of fHbp), f-N (N-term of fHbp with the C-term of NHBA). 
Western blot analysis of total lysates collected were loaded on a SDS gel and transferred on nitrocellulose 
membrane, stain was performed with both B) α-NHBA polyclonal sera (1:2000) and C) α-fHbp polyclonal sera. 
Arrows highlighted fusion proteins. * aspecific band 
A) 
B) C) 
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In the N-f fusion surface expression was confirmed using the α-NHBA polyclonal sera confirming 
its ability to be translocated onto the surface likely due to the presence of the β-barrel from 
fHbp. Instead the fHbp C-terminal is not readily recognized on the surface possibly due to its 
cleavage and release in the supernatant because the two serine cleavage sites are included in the 
NHBA N-terminal portion (Figure 10.A). The f-N fusion was detectable on the bacteria surface 
either with α-NHBA and α-fHbp polyclonal sera (Figure 10.B) confirming the expression and the 
presence of NHBA β-barrel domain, which was not detectable by Western blot with α-NHBA 
polyclonal sera (Figure 8.A). Expression levels detectable on the bacteria surface of f-N fusion 
suggest that the reason why f-N fusion was not readily detectable by Western blot using the 
NHBA antisera might be due to the low levels of the expression reached. 
In summary these data suggest that the C-terminal β-barrel domain is necessary for the delivery 
on the surface of the N-terminal portion of the analyzed lipoproteins and that the β-barrel of 
NHBA or fHbp is functionally interchangeable in this necessary role.  
Figure 10 C-terminal β-barrel is required for N-terminal domain surface tranlsocation. FACS analysis on fixed 
bacteria were performed with both α-fHbp (1:1000) and α-NHBA polyclonal sera (1:800) and subsequently with 
FITC-labeled anti-mouse secondary antibodies. A) N-f fusion was detectable only with α-NHBA sera, because 
fHbp portion was cleaved out. B) f-N was detectable on the surface by both sera. 
A) 
B) 
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3.3 Surface lipoproteins assembly modulator 1 (Slam1) expression is 
conserved among N. meningitidis strains 
Slam1 was recently identified from Hooda and coworkers as the key component for the surface 
localization of specific SLPs in group B N. meningitidis [59]. The sequence of Slam1 from MC58 
was cloned into an expression plasmid and after recombinant expression in E. coli, the protein 
was purified from the inclusion bodies (IB) as described in material and methods (7.4). Purified 
protein was loaded on SDS gel page (Figure 11) and colored with coomassie safe blue staining 
and its purity was estimated as >90%. The eluted protein was concentrated ten time and then 
used to immunize mice for the generation of polyclonal sera for use in further experiments.  
 
In order to characterize better the function of this protein, the Slam1 gene was deleted in the 
MC58 strain. The knockout (ΔSlam1) was obtained by replacing the Slam1 gene with an 
antibiotic resistance cassette as described in the material and methods section (7.2.1). Western 
Blot analysis on total lysates of the MC58 (WT) and the ΔSlam1 strains as well as on outer 
membrane vesicles (OMVs) from MC58 stained with α-Slam1 polyclonal sera (Figure 12.A) 
indicated the correct deletion of the gene in ΔSlam1 strain, and as expected Slam1 was present in 
the OMV preparation confirming its presence in the outer membrane. Interestingly while Slam1 
was in the OMVs, FACS analysis with α-Slam1 antibodies was negative, suggesting that Slam1 is 
not exposed enough to be recognized on the surface by the antibodies (Figure 12.B). 
In order to understand whether Slam1 was conserved among different group B meningococcal 
strains, we expanded our analysis to a broader panel of clinical isolates from different clonal 
complexes. Strain characteristics are summarized in Table 2. As showed in the Western blot, 
Slam1 was detectable at comparable levels in all the analyzed strains (Figure 12.B) 
 
Figure 11 Recombinant Slam1 protein purification. SDS Gel page  
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Table 2 N. meningitidis panel of strains tested for Slam1 expression with characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
Clonal 
Complex 
Geography Year 
PorA 
variant 
fHbp 
variant 
NHBA 
variant 
Nad A  
MC58 ST-32 GBR 1985 7 1.1 p3 +,v1 
NGH38 ND NOR 1976 18-1 2.24 p2 - 
M02441 ST-269 USA 1996 12 3.31 p19 - 
M10792 ST-11 USA 2003 22.14 2.22 p139 +, ND 
M07-0241076 ST-11 GBR 2007 5-1 10.8 2.23 p20 +, v2 
LNP-24447 ST-11 FRA 2008 5.2 3.31 p29 +, ND 
UK 104 ST-35 GBR 2008 7.2 4 2.16 p21 - 
M11053 ND USA 2003 22.9 2.19 p17 - 
M11 295 ST-32 USA 2003 7.16 1.1 p5 +, v1 
M02934 ST-32 USA 1996 7.16 1.1 p5 +, v1 
M10994 ND USA 2003 16.2 2.19 p17 - 
        
Figure 12 Slam1 expression. A) Western blot anlysis. Total lysate from MC58 WT, ΔSlam1 and 1µg of MC58 
OMvs preparation were loaded on SDS gel page and trasferred on a nitrocellulose membrane, stained with 
polilclonal sera α-Slam1 (1:1000). B) FACS analysis on fixed bacteria, they were first stained with α-Slam1 
policlonal sera (1:1000) and subsequently with FITC-labeled anti-mouse secondary antibodies (1:1000). C) 
Western blot with α-Slam1 polyclonal sera (1:1000) on a panel of group B N. meningitidis strains.  
 
C) 
A) B) 
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3.4 Slam1 has a role in the stable expression as well as in the translocation 
to the surface of fHbp 
The MC58 clinical isolate, normally used as a laboratory strain, is characterized by high 
expression levels of fHbp and low NHBA amount. The Slam1 knock-out was generated also in 
NGH38 N. meningitidis strain, a representative carrier isolate, which expresses high NHBA levels 
and low fHbp levels. We grew MC58 WT, ΔSlam1 and NGH38 WT, and ΔSlam1 until exponential 
phase and fixed bacteria and whole cell lysates were collected. OMVs from stationary phase 
were also collected as described in the material and methods (7.9.1) and included in the 
Western Blot analysis. FACS analysis on fixed bacteria showed a marked reduction in fHbp 
displayed on the surface in the ΔSlam1 strains for both MC58 and NGH38, validating the 
previous results observed from Hooda et al. (Figure 13) 
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Figure 13 fHbp is not surface exposed in ΔSlam1. FACS analysis on fixed bacteria were first stained with α-fHbp 
polyclonal sera (1:1000) and subsequently with FITC-labeled anti-mouse secondary antibodies (1:1000). FACS 
analysis was represented as A) histograms and B) column graphs with the mean fluorescence intensity. WT 
strain stained only with 2° Ab was use as a negative control in the analysis 
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Western blot revealed that the amount of fHbp was strongly decreased in the absence of Slam1 
(Figure 14). A very slight band was still visible in the MC58 ΔSlam1 total lysate whereas in 
NGH38 ΔSlam1 fHbp was almost undetectable in the total lysate, probably due to the lower 
initial fHbp expression levels.  
Western blot on OMVs preparation confirmed the differences in fHbp amount between WT and 
ΔSlam1 was maintained also in the OMVs, furthermore the presence of fHbp in the OM was 
confirmed. Taken together these data suggest that Slam1 has a critical effect on the amount of 
fHbp expressed per se and the low amount of fHbp on the surface might be due a general 
decrease of fHbp amount in the bacteria in the absence of Slam1 and not only to a 
mislocalization of fHbp. 
 
To further investigate this general reduction of fHbp protein amount in the bacteria, analysis of 
fHbp RNA transcript levels was performed by qRT-PCR. We grew all strains (MC58 and NGH38, 
WT and ΔSlam1) in GC media until exponential phase and we took samples for RNA extraction 
and Western blotting.  
  
Figure 14 fHbp amount decreased in the ΔSlam1 recombinant strains. Western Blot using α-fHbp polyclonal 
sera performed WT and ΔSlam1 in MC58 and NGH38 N. meningitidis strain on A) total lysate derived from 
bacteria growth in GC liquid media until exphonential phase. B) 1µg of OMVs shows the same trend to 
reduced fHbp amount. Total lysates were stained also with α-2091 used as a loading control.  
B) A) 
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While there was a slight trend for less RNA in the Slam1 mutants, this reduction was not 
statistically significant. The differences observed in the RNA transcription levels from WT vs 
ΔSlam1 were not enough to justify the decrease in fHbp protein amount observed by Western 
blot analysis (Figure 15), this suggests that in the absence of Slam1 there is a greater turnover of 
the fHbp protein possibly due to an fHbp instability when blocked in the periplasmic space. 
 
 
 
 
 
 
 
 
 
 
 
  
B) A) 
Figure 15 fHbp reduction is not regulated at the transcription level. A) Western Blot using α-fHbp polyclonal 
sera performed on total lysate derived from bacteria growth in GC liquid media until exphonential phase. 
Bacteria were stained also with α-2091 as a loading control. B) fHbp RNA steady state levels were quantified by 
qRT-PCR and relative expression levels were determined normalizing to 16S-rRNA. Data set represented is 
representatives of 2 independent experiments. 
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3.5 NHBA and Mip are two newly identified substrates for Slam1 
In the Neisseria genus, many lipoproteins are known to be surface localized. Some of them were 
already identified as Slam1 or Slam2 substrates [59], so we decided to check if some of the other 
identified SLPs were also Slam1 substrates. We focused our attention first of all on NHBA, 
because it exhibits the same β-barrel structure of the other Slam1 substrates [84], and as shown 
previously, it was necessary for NHBA surface localization. Secondly we focus our attention on 
Mip (Macrophage Infectivity potentiator) since it was described to be translocated on the 
surface in N. gonorrhoeae  [83], and we checked whether the meningococcal homologue [89] 
was also surface localized.  
We grew MC58 WT and ΔSlam1 in GC medium until 0.5 OD600/ml and samples for Western 
blotting and FACS analysis were collected. Western blot of MC58 OMVs, WT and ΔSlam1, was 
also included in the analysis to confirmed the correct delivery in the OM. 
 
Contrary to fHbp, from total lysates there is no difference in the expression of NHBA in the 
absence of Slam1, and interestingly NHBA is present at higher quantities in OMVs in the Slam1 
mutant (Figure 16.A). However FACS analysis showed that no NHBA was detectable on the 
Figure 16 NHBA is translocated on the surface by Slam1 in MC58. A) Western blot on the total lysate and 
1µg of OMVs were stained using α-NHBA polyclonal sera (1:2000) and confirmed the expression of NHBA 
and the presence in the OM in both strains. Arrows highligth NHBA full length and the truncated forms. B) 
FACS analyis on fixed bateria bacteria were first stained with α-NHBA polyclonal sera (1:800) and 
subsequently with FITC-labeled anti-mouse secondary antibodies (1:1000). NHBA was not display on 
bacteria surface in MC58 ΔSlam1 strain. FACS analysis was visualized both as histogram with the percentage 
of max and as mean fluorescence. * aspecific band. 
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bacteria surface when Slam1 was not expressed, confirming the role of Slam1 in NHBA surface 
localization (Figure 16.B). This suggests that, in the absence of surface expression in the Slam1 
mutant, NHBA appears to accumulate in the OMVs likely due to the absence of turnover from 
external proteases. 
Western blot analysis of the total lysates indicated that Mip was stably expressed either in the 
WT or in ΔSlam1 and was delivered to the outer membrane as it was present in the OMVs 
preparation (Figure 17.A), but no Mip was detectable on the bacteria surface (Figure 17.B), 
confirming the role of Slam1 also in the translocation of Mip on MC58 bacterial surface.  
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Figure 17 Mip is translocated on the surface by Slam1 in MC58. A) Western blot on the total lysate and 1µg of 
OMVs were stained using α-Mip polyclonal sera (1:1000) confirmed Mip expression in both strains. B) FACS 
analyis on fixed bateria bacteria were first stained with α-Mip polyclonal sera (1:1000) and subsequently with 
FITC-labeled anti-mouse secondary antibodies (1:1000). Mip was not display on bacteria surface in MC58 
ΔSlam1 strain. FACS analysis was visualized both as histogram with the percentage of max and as mean 
fluorescence.  
A) 
B) 
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3.6 Surface exposure of fHbp, NHBA and Mip can be controlled by 
modulation of Slam1 expression 
To further investigate the role of Slam1 in the surface localization of NHBA and Mip we 
complemented the MC58 ΔSlam1 strain by inserting a Slam1 gene under the control of an IPTG-
inducible promoter into the genome as described in the material and methods (7.3.1).  
MC58 WT, ΔSlam1 and the complemented strain (CiSlam1) were grown in liquid medium in the 
presence of increasing IPTG concentrations until exponential phase and total lysates for Western 
blot analysis and fixed bacteria for FACS analysis were collected. We were able to restore Slam1 
expression in ΔSlam1 background and to increment Slam1 expression at the high IPTG 
concentration (0.1 and 1 mM) to higher Slam1 expression compared to WT expression level 
(Figure 18).  
 
From the same samples, Western blot and FACS analysis were performed to observe how fHbp, 
NHBA and Mip responded to the different Slam1 expression levels (Figure 19).  
As expected, fHbp expression was not visible in ΔSlam1 mutant strain, whereas its expression 
was restored at comparable levels to the WT in the complemented strains. From FACS analysis, 
fHbp surface localization was depending on Slam1 induction and only at the highest IPTG 
concentration we completely restored fHbp exposure on the surface at comparable levels to the 
WT (Figure 19.A). For Mip, in which no differences in the expression levels were observed in 
WB, surface localization was depending on Slam1 induction (Figure 19.B). Also NHBA surface 
translocation was depending on Slam1 expression. Furthermore, in contrast with the others 
SLPs, at the highest IPTG concentration (0.1 and 1 mM of IPTG) we could see higher amounts of 
NHBA on the surface compared to the WT strain (Figure 19.C).  
It is worth noting that for NHBA, we observed a different cleavage pattern in the presence of 
different Slam1 amounts. In the absence of Slam1, or at low levels of induction, we observed a 
greater cleavage of NHBA, while in the presence of Slam1 (WT or high induction levels) more 
NHBA full length was present. Interestingly this suggests that we get highly processed when it is 
not exposed on the surface. 
Figure 18 Slam1 can be over expressed in MC58. MC58 WT, ΔSlam1 and CiSlam1 were growth in GC 
liquid medium in the presence of IPTG (0; 0.001; 0.01; 0.1; 1 mM). Western blot of the total lysate stained 
with α-Slam1 (1:1000). Slam1 expression was restored in the complemented strain. 
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We then analyzed how NGH38 N. meningitidis strain was responding to Slam1 inductions by 
restoring expression with complementation in the NGH38 Slam1 mutant (Figure 20). NGH38 
strains were grown as previously, with different IPTG concentrations in GC liquid media, and 
samples for Western Blot and FACS analysis were collected.  
 
 
 
Figure 20 Slam1 can be over expressed in NGH38. NGH38 WT, ΔSlam1 and CiSlam1 were grown in GC 
liquid medium in the presence of IPTG (0; 0.001; 0,01; 0,1; 1mM). Western blot of the total lysate stained 
with α-Slam1 (1:1000). Slam1 expression was restored in the complemented strain. * aspecific band 
Figure 19 SLPs surface exposure can be modulated by Slam1 expression in MC58. MC58 WT, ΔSlam1 and 
CiSLam1 strain were analyzed for A) fHbp, B) Mip and C) NHBA expression by WB and surface localization 
by FACS using FITC α-mouse secondary antibody. FACS analysis were reported as mean fluorescence and as 
histogram with the percentage of max. Histogram colour key: Negative control (grey,); WT (pink) ΔSlam1 
(blue), Ci0313 with IPTG 0 (orange); 0.001 (green); 0.01 (red); 0.1 (yellow); 1( light blue). *aspecific band 
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Previous results were confirmed in the NGH38 strain, where fHbp and NHBA surface localization 
can be modulated by Slam1 induction (Figure 21). Furthermore in NGH38 at the highest Slam1 
induction the translocation of SLPs on the surface was higher for both fHbp and NHBA as 
compared to WT. 
Interestingly also in NHG38 by Western blot, an inverted trend in the accumulation of the 
different NHBA forms was visible: decreased amount of NHBA truncated forms was followed by 
an accumulation of NHBA full length in the presence of Slam1 and the restoration of surface 
localization.  
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Figure 21 SLPs surface exposure can be modulated by Slam1 expression in NGH38. NGH38 WT, ΔSlam1 
and CiSlam1 strain were analyzed for A) fHbp and B) NHBA expression by WB and surface localization by 
FACS. FITC α-mouse was used as secondary antibody. FACS analysis were reported as mean fluorescence 
and as histogram with the percentage of max. Histogram colour key: Negative control (grey,); WT (pink)  
ΔSlam1 (blue), Ci0313 with IPTG 0 (orange); 0.001 (green); 0.01 (red); 0.1 (yellow); 1( light blue). *aspecific 
band 
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3.7 Mip is not translocated to the Outer membrane in NHG38  
When we analyzed Mip surface localization in NGH38 strains, surprisingly we noticed that Mip 
was not detectable on the surface even in the NGH38 WT strain (Figure 22.A).  
 
Western Blot analysis with total lysate from MC58 WT, ΔSlam1 and NGH38 WT, ΔSlam1 stained 
with α-Mip polyclonal sera, confirmed Mip expression in all strains (Figure 22.B). However, 
from western blot analysis it was also possible to notice that Mip from NGH38 strains showed 
lower molecular weight compared to Mip expressed in MC58.  
Western blot on OMVs from both WT and ΔSlam1 showed that Mip was not present in NGH38 
OMVs preparation, suggesting that, in this strain Mip is not translocated to the OM (Figure 
22.C).  
The Mip gene sequence from NGH38 were sequenced and the results indicated that NGH38 
(Figure 23) has a deletion of four amino acids close to the lipobox motif as well as two point 
mutations within the coding sequence. The first one was in proximity to the deletion, a Serine (S) 
was exchanged with an Alanine (A); and the second in the middle of the sequence, in which an 
Aspartic acid (D) was replaced by a Glutamic acid (E) (Figure 23).    
Interestingly this suggests that these sequences may be important signals for lipoproteins 
localization in this bacterium. 
 
 
 
 
 
 
 
Figure 22 Mip is not translocated to the outer membrane in NGH38. NGH38 strains were grown in GC 
liquid media until exponential phase, total lysate and fixed bacteria were collected. A) Facs analysis of 
NGH38 with α-Mip polyclonal sera and subsequently with FITC α-mouse secondary antibody. Wester Blot of 
B) total lysate and C) 1µg of OMVs stained with α- Mip polyclonal sera. 
A B C 
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Figure 23 Mip amino acid sequence aligment.  NMB1567 aminoacid sequence from NGH38 was aligned 
with the aminoacid sequence of MC58. Red box shows conserved lipobox motif. 
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3.8 Slam1 has a role in bactericidal activity by influencing SLPs 
localization in N. meningitidis 
In order to test how Slam1 expression and the resultant different exposure of SLPs on the 
surface may alter the immunogenicity of OMVs, OMV preparations from the NGH38 panel of 
strains (WT, ΔSlam1 and CiSlam1) were purified and included in an immunization scheme in 
mice. NGH38 strains were grown as described in the material and methods (paragraph 7.9.1). 
Complemented strain was grown in the presence of 0.1mM of IPTG. OMVs were purified, and 
analyzed by SDS gel page (Figure 24).  
 
OMVs showed comparable pattern of protein bands among preparations. Slam1 overexpression 
was visible in the complemented strain even in a SDS Gel page stained with coomassie safe blue, 
but other than that there were no significant differences in proteins profile among OMVs 
preparations. 
These OMV preparations were used to immunize mice according to the scheme summarized in 
Figure 25. In short, CD1 mice were immunized with two doses of 2.5 µg of OMVs 
intraperitoneally. The sera collected 14 days post the second immunization were tested for 
bactericidal activity in the presence of rabbit complement (rSBA) (paragraph 7.14) and by ELISA 
(paragraph7.13) for the presence of fHbp and NHBA antibodies. 
 
Figure 24 SDS gel page of NG38 OMVs preparation. 7µg of OMVs were loaded on SDS gel page and stained 
with comassie safe blue. Marker used was SeeBLue Nu page. 
37 
 
 
rSBA analysis was performed on the pooled sera against a panel of strains, selected to be 
representative as divergent for the major antigens and clonal complex. Strains characteristics 
are summarized in Table 3.  
Both the homologous NGH38 strain, and the 4 other heterologous strains from different clonal 
complexes and expressing diverse PorA variants were tested in serum bactericidal assay with 
rabbit complement. 
 
 
 
 
 
 
 
 
 
 
As was shown in Figure 26 no bactericidal activity was detected against three different strains 
(MC58 NZ98/254 and DE8221) probably due to high differences from NGH38 and the tested 
strains. However, high bactericidal titers were observed against the homologous strain NGH38 
and the heterologous 5/99 strain which expresses a different PorA subtype. Interestingly, 
pooled sera from mice immunized with ΔSlam1 showed slightly lower titers against the 
homologous strain, and no bactericidal activity was measurable against the 5/99. 
Complementation of the mutant restores high titers against the homologous (NGH38) and 
heterologous (5/99) strain.  
 
 
Table 3 
     TABLE OF STRAINS TESTED 
  
Clonal 
Complex 
PorA variant 
fHbp 
variant 
NHBA 
variant 
Nad A 
variant 
MC58 ST-32 7 1.1 p3 +,v1 
NGH38 NA 18-1 2.24 p2 - 
NZ 98/254 ST-41/44 7-2 1.14 p2 - 
DE8221 ST-231 5 2.24 p2 - 
5/99 ST-8 5.2 2.23 p20 +, v2 
      
Figure 25 Immunization scheme. Upper panel: Eight CD-1 mice were immunized intra-peritoneally (IP) two 
times, as indicated. Bottom panel: composition of OMVs formulations. 
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rSBA assay performed with single mice from the three immunization groups against NGH38 and 
5/99 strains shows the same trend observed with pooled mice sera. Again a slight but significant 
decrease in the bactericidal activity was observed against the homologous strain (NHG38) 
(Figure 27. A); while no bactericidal titers were elicited against the heterologous strain (5/99) 
in the absence of PorA mediated killing (Figure 27.B). 
 
 
  
Figure 27 Serum bactericidal activity (SBA) with single mice performed against 5/99 and NGH38 WT Neisserial 
strains. A) rSBA against NGH38 reference strains. Statistical analysis performed with multiple comparison was 
not significant. While analyzing each component with t test student non parametric, (Mann-Whitney test) WT 
and ΔSlam1 was significant ( * p value 0.0193); ΔSlam1 and CiSlam1 was not significant (ns). B) rSBA against 
5/99 reference strains. Statistical analysis was performed using Kruskal-Wallis multiple comparisons test **p: 
0.0033 (WT vs ΔSlam1) and p: 0.0010 (ΔSlam1 vs CiSlam1)  
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Figure 26 Serum bactericidal activity (SBA) performed on a panel of strains. 
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To further investigate whether the Slam1-dependent bactericidal activity could depend on 
different NHBA and/or fHbp surface localization we performed rSBA on a panel of 5/99 strain 
with the over-expressing NHBA variant p2 or lacking fHbp and NHBA (Figure 28).  
 
No differences in bactericidal activity of the pooled sera were observed among the tested WT or 
recombinant 5/99 strains, suggesting that neither α-NHBA nor α-fHbp antibodies were 
mediating the killing activity of the OMVs immune-sera. 
 
ELISAs were performed on the individual sera on plates coated with NHBA and fHbp proteins, 
however, no anti-fHbp nor anti-NHBA titers were measurable from any of the sera of the study 
(data not shown). 
In summary, we conclude that Slam1 has a drastic effect on the immunogenicity of OMVs. In 
NGH38, Slam-dependent responses are independent of PorA-driven responses and may be 
through the surface translocation of bactericidal antigens, likely Slam1-dependent lipoproteins 
other than NHBA and fHbp. 
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Figure 28 Serum bactericidal activity (SBA) performed on a panel of strains. Except for 5/99 WT all other 
tested strains were all deleted for NadA antigen. WT sequence of NHBA (5/99 ΔNHBA) and fHbp 
(5/99ΔNHBAΔfHbp) was also removed. In 5/99ΔoeNHBAp2 NHBA variant p2 was complemented ex-locus 
under the control of an IPTG inducible promoter in a 5/99 ΔNadAΔNHBA background.  
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 Discussion and conclusion 4
The main aim of this work was the characterization of the lipoproteins translocation 
mechanisms in N. meningitidis. Several aspects were investigate: we investigated sorting signals 
for Neisserial lipoproteins localization; we better characterized the role of Slam1 for 
lipoproteins surface exposure and identify two new targets; and we test whether Slam1 
influences the immunogenicity of OMVs by modulating SLPs on the surface.  
E. coli have been largely used as a model to investigate translocation signals and mechanisms of 
lipoproteins localization system [90]. However not all Gram negative bacteria, share the same 
features: sometimes they have conserved the general pathway and differ in signals [56] or 
translocator components [46]. From the evidence presented here this would seem to be the case 
also for N. meningitidis. While homologues of the E. coli Lol components can be identified in N. 
meningitidis [58], from our systematic lipoprotein analysis we predict that lipoproteins are over-
represented in N. meningitidis (at over 3% of the total number of ORFs) compared to E. coli. 
Furthermore from consolidating known proteomic data we show that the +2 rule does not hold 
true as a retention signal for the IM. Through the unexpected result of the absence of Mip on the 
bacteria surface in the NGH38 strain, we serendipitously identify that the area +8-and +11 may 
be important for IM retention. Indeed analyzing whole cell lysate and OM preparation (OMVs) 
from MC58 and NGH38, Mip was stably expressed in both strains, but was not present in the 
OMVs preparation from NGH38 indicating that a 4 amino acid deletion (+8;+11) alters 
significantly the translocation of this lipoprotein and abrogates translocation to the OM in this 
strain. The deletion in this area may result in the generation of a retention signal or compromise 
the recognition by LolCE and blocked the surface lipoprotein at the level of the inner membrane. 
This hypothesis should be further tested in order to elucidate the precise signals for lipoproteins 
localization in N. meningitidis.  
The presence of surface lipoproteins and the recent Slam OMP family identified by Hooda and 
co-workers, pointed out the presence of additional mechanisms for surface localization in 
Neisseria. Here we show that Slam1 was stably expressed in different N. meningitidis clinical 
isolates either invasive or carriage meningococcal strains. We also identify two new substrates 
for Slam1, NHBA and Mip. Indeed both NHBA and Mip were stably expressed in the Slam1 
mutant but not translocated on bacteria surface when Slam1 was missing. 
Since some Slam1 substrates show similar β-barrel domain structures [49] we hypothesize that 
the signal for surface localization was present in the common domain. The C-terminal domain 
structure of NHBA has been reported [84] and, as the other Slam1 substrate, is folded with a 
TbpB-like structure. Our data show that in the absence of the β-barrel C-terminus, truncated 
forms of NHBA were not able to be exposed on bacterial surface indicating the β-barrel is 
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essential for surface localization. To further investigate this aspect, we generated different SLPs 
mutants in which the C-terminal portion was exchanged, among surface lipoproteins. The 
importance of the C-terminal domain was confirmed, indeed when C-terminal domains were 
replaced between NHBA and fHbp, both fusion proteins were able to reach bacteria surface. All 
these results were support the hypothesis that the C-terminal portion and the β-barrel domain 
play a major role in the interaction whit Slam1 for SLP translocations across the OM.  
Additionally we proved that meningococcal Mip lipoprotein [89], which was described to be 
surface exposed in N. gonorrhoeae [83], was depend on Slam1 for its surface exposure in N. 
meningitidis. No structure was available for Neisserial Mip, but a model based on the structure 
from L. pneumophila homologous has been described [89]. Meningococcal Mip consist in a 
globular C-terminal with the functional domain, and a long α-helix domain involved in Mip 
dimerization. From this model Mip was not folded with a TbpB-Like shape, unlike the other 
identified Slam1 substrates. This suggested that not all of the β-barrel domain may be necessary 
for recognition and delivery of SLPs to bacteria surface and possibly conserved elements may be 
present in Mip and the β-barrel and it is possible that only few amino acids, with similar 
characteristic or specific folding, can be necessary for the recognition and/or requirement from 
Slam1. 
As mentioned before we were able to identify two new Slam1 substrates NHBA and Mip that 
were stably expressed and only their surface localization were affected depending on Slam1 
expression. On the contrary for fHbp results demonstrated a general decrease in the fHbp total 
amount in the ΔSlam1, and not only in its surface exposure. This observed reduction was 
conserved among tested strains and was not driven from feedback mechanisms at 
transcriptional levels, as no significative differences in the transcription level was observed in 
the analyzed strains between WT and ΔSlam1. This suggests that Slam1 directly or indirectly has 
an effect on the turnover or stability of fHbp protein post-transcriptionally.  
While the precise reason for this is unknown, that the stability of fHbp is affected positively by 
Slam1 and this phenomenon is specific only for fHbp, of the three SLPs tested here. This could be 
related either to a direct mechanism: it is possible that Slam1 directly interacts with fHbp 
thereby stabilizing the protein, or due to an indirect mechanism: fHbp degradation from 
proteases present in the periplasm when not localized on the surface.  
Lipoproteins are emerging as key targets for protective immunity [91]. We have identified 2 
other Slam1 substrates and probably other SLPs remain not yet identified. Our data suggests 
also the possibility to modulate lipoprotein exposure by regulating Slam1 expression. Moreover 
the over-expressing of Slam1 gave evidence of a concomitant increase of lipoproteins on 
bacteria surface compared to the WT condition. To test whether different levels of SLPs on the 
surface might affect immunogenicity we tested the immunogenicity of OMVs purified from 
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strains with and without Slam1. Rabbit- serum bactericidal activity (rSBA) performed on a panel 
of strains confirmed the role of Slam1 in driving bactericidal activity of the OMVs. There was a 
small but significant reduction in bactericidal activity against the homologous strain in sera 
raised against OMVs lacking Slam1. PorA is recognized as an immunodominant antigen of 
meningococcus and generally OMVs will be protective towards strains with similar PorA 
subtypes. From our data, we can conclude however that Slam1 contributes to full bactericidal 
activity against the NHG38 strain. We tested 4 heterologous strains all with different subtypes to 
investigate the immunogenicity of non-PorA antigens in the OMVs. Some strains (MC58, NZ 
98/254 and DE8211) were not killed by any of the OMV antisera, probably due the high 
differences within NGH38 strain. On the contrary, other 5/99 strain was killed with high titers 
from sera derived from NGH38 WT OMVs, indicating that NGH38 OMVs contain non-PorA 
bactericidal antigens which cross-react with 5/99. Surprisingly, all bactericidal activity against 
5/99 was dependent on Slam1, and OMVs prepared from Slam1 mutant were not bactericidal. 
Further analyses revealed also that immunogenicity was not driven by NHBA or fHbp, as no 
NHBA and fHbp antibodies were detected by ELISA and the 5/99 lacking NHBA and fHbp 
expression was still killed by OMV sera.  
Since all strains expressed Slam1 to similar extent with conserved sequence, it is unlikely that 
bactericidal activity was driven by Slam1. Furthermore, FACS analysis indicated that Slam1 is 
not surface exposed and accessible to polyclonal antisera, suggesting that Slam1 maybe not act 
directly as a target for bactericidal antibodies. These results together suggest the presence of 
bactericidal SLPs, which are Slam1 substrates distinct from NHBA and fHbp, that can have a role 
in OMVs immunogenicity. 
Many aspects have to be further investigated and characterized. How Slam1 interact with SLPs is 
still an open question. No Slam1 homologous were identified so far [63] in B. burgdorferi and 
Selverda et al. have published that the N-terminal part of fHbp was enough for the successful 
surface display of Borellia OspA on meningococcal OMVs [91], in contrast to what we have 
discovered about the importance of the C-terminal domain. In our hands truncated forms of 
NHBA where stably expressed but not delivered on bacterial surface. On the other hand this 
could be in agreement with the ability of Slam1 to translocate Mip on the surface even if is not 
folded with TbpB-like structure. These results might suggest an additional role of the N-terminal 
portion for recognition and surface translocation for some SLPs.  
In summary, signals for inner membrane retention or outer membrane translocation are distinct 
in N. meningitidis with respect to the E. coli model and more research is needed to fully elucidate 
these. The identification of Mip as a Slam1 substrate and its mutant allele in NGH38 could help in 
the future to characterize meningococcal SLPs as well as the signal for IM retention. Here we 
have widened our knowledge on Slam1 substrates, and the immunogenicity studies suggest that 
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other Slam-dependent bactericidal SLPs might be present in N. meningitidis. Lipoproteins 
present on bacteria surface represent a key target for protective immunity so the new Slam1 
translocator component identified in many gram negative bacteria might represent a new 
powerful strategy for engineer bacteria for over-expressed immunogenic lipoproteins on 
bacteria surface.  
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Chapter Two  
 
Exploiting Slam1 for heterologous 
Over-Expression of Neisserial 
Surface exposed lipoproteins 
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Outer Membrane vesicles (OMVs) are small particles spontaneously released from bacterial 
membranes, in particular from Gram-negative bacteria. They are often considered a non-
replicative representation of the parent bacterium as they contain Outer Membrane Proteins 
(OMPs) and oligosaccharides, present on the bacterial surface. OMVs contain innate 
immunostimolatory properties able to facilitate the immune system activation; hence OMVs 
purified from several pathogens are able to induce protective immune responses against the 
pathogen from which they are purified from [80, 92, 93]. In the table1 are reported some 
examples of OMVs from different bacteria able to elicitates a functional immune response.   
 
Table 4 Overview OMVs vaccine tested in mice or other rodents. Spontaneous released (s-
OMVs), detergent extracted (d-OMVs) and native (n-OMVs) extracted with detergent free 
methods.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Thanks to the ability to genetically engineer the OMVs-producing bacteria, this system proves to 
be versatile to be exploited as a vaccine platform [80, 81]. In the past, many approaches were 
investigated for the expression of heterologous antigens using OMVs as a delivery system within 
their lumen or their surface [105]. Surface localization seems to be preferred for the generation 
of functional antibodies against the carried antigens [106-108] and for this purpose different 
strategies were developed. In general, antigens or proteins normally founded on bacterial outer 
membrane, totally or partially exposed on the surface, might be used for the surface delivery of 
foreign antigens in heterologous or homologous systems. For example Kim and co-workers were 
Pathogen 
type of 
OMVs 
reference 
Acinetobacter 
baumannii s-OMVs [94] 
Bordetella pertussis d-OMVs  [95] 
Borrelia burgdorferi n-OMVs [96] 
Brucella melitensis s-OMVs [97] 
Burkholderia 
pseudomallei s-OMVs [98] 
Francisella s-OMVs [99] 
Helicobacter pylori and 
H. felis s-OMVs [100] 
Klebsiella pneumoniae s-OMVs [78] 
Neissieria meningitidis s-OMVs [101] 
Salmonella 
typhimurium s-OMVs [74] 
Shigella s-OMVs [102, 103] 
Vibrio cholerae s-OMVs [104] 
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able to delivery GFP molecules on OMVs surface taking advantage of E. coli ClyA (vesicles 
associated toxins) [109] and the same system was use to delivery Influenza A antigen on vesicles 
surface [110]. Other approaches involved autotrasporter proteins. As the name suggests, this 
class of protein contains a translocator domain, which span the OM, and is responsible for self-
transport of the passenger domain on bacterial surface. In this case, the antigen could be fused at 
the level of the passenger domain and displayed on bacteria surface thanks to the translocator 
domain [111, 112]. A similar approach was described by Salverda and co-workers that were able 
to display OspA, B. burgdoferi surface lipoprotein, on meningococcal surface by fusing it to 
different portion of Neisserial fHbp surface lipoprotein [91]. Interstingly different unrelated 
studies also find antibody-mediated immune responses against luminal heterologous antigens 
[113-115]. 
Lipoproteins are molecules characterized by an acyl moiety, either di- or tri- acylated, at the N-
terminal portion of the proteins, which allows their anchoring to the membrane. The 
mechanisms by which lipidated lipoproteins can reach the Outer Membrane (OM) is conserved 
among bacteria and involves the Lipoprotein outer membrane localization (Lol) system; 
composed by an ABC transporter (Lol CDE) at the levels of IM, a chaperonine (LolA) and a 
lipoprotein (LolB) able to transfers lipoproteins from LolA and anchors them to the inner leaflet 
of the OM [30]. Lipoproteins are usually found to be attached to the Outer Membrane (OM) or 
the Inner Membrane (IM) facing the periplasm, but the number of reports regarding lipoproteins 
anchored to the outer leaflet of the OM has increased in the last years, highlighting the 
importance of this emerging class of lipoproteins named Surface Lipoproteins (SPLs)[39, 57].  
The SLPs identified up to date [49, 116-124] are highly heterogeneous, lack common features 
and the mechanism of OM translocation seems to be different among bacteria [40]. SLPs can be 
partially surface exposed, as for E. coli RcsF [48], or transiently display on surface like E. coli Lpp 
and Pal [125, 126] or nontypeable H. influenza P6 lipoproteins [127]. SLPs from Neisseria genus 
are the most studied group of this lipoprotein family. Eight different SLPs have been 
experimentally localized on Neisserial surface [49, 53, 83, 128], among them factor H binding 
protein (fHbp) [19] and Neisseria Heparin binding antigen (NHBA)[50]. Both fHbp and NHBA 
are antigens against N. meningitidis serogroup B [128, 129], demonstrating the importance of 
SLPs as vaccine antigen.  
Recently a family of outer membrane proteins called Slam (Surface-lipoprotein assembly 
modulator), involved in surface exposure of specific N. meningitidis lipoproteins was described 
[59]. N. meningitidis contains two different Slam proteins: Slam1 which is necessary for the 
translocation of different meningococcal SLPs and Slam2 which is specific for HpuA 
(hemoglobin-haptoglobin utilization protein A) translocation. Hooda and colleagues showed the 
ability of Slam to potentiate the functional display of selected SLPs on E. coli laboratory strain, 
47 
 
which does not possess any Slam or SLPs homologous [63]. Hooda shows the capacity of Slam1 
to localize fHbp and other N. meningitidis SLPs on the surface of non-pathogenic E. coli [59]. On 
the contrary Fantappiè and co-workers have recently reported the ability of N. meningitidis fHbp 
and NHBA to reach E. coli surface even when Slam1 was not expressed, suggesting the presence 
of a sub-class of SLPs which can always cross outer membrane, even when transplanted from 
one organism to another [130]. 
 
In this work, taking advantage of the recently identified Slam1 translocator component, and 
using strategies of co-expression with SLPs in the heterologous background of E. coli, we were 
able to generate OMVs differentially enriched in immunogenic SLPs and potentially with 
different localization (surface exposed or in the lumen of OMVs) of these SLPs.  
The hypothesis investigated is therefore whether the co-expression of meningococcal SLPs with 
Slam1 generates more immunogenic E. coli OMVs. We clearly demonstrate the importance of the 
co-expression of SLPs with Slam1 for the correct display of antigens and we demonstrate that, 
depending on the presence of Slam1, heterologous E. coli OMVs enriched with N. meningitidis 
SLPs elicit different antibody responses. 
  
48 
 
5 Results 
5.1 Co-expression of Neisserial SLPs with Slam1 in E. coli results in high 
expression and their translocation to bacterial surface 
5.1.1 Slam1 has a role in the stable expression as well as in the translocation to the 
surface of fHbp 
The ultimate goal of this study was to generate E. coli OMVs able to display SLPs such as fHbp or 
NHBA on their surface, and to investigate the role of Slam1 in promote the heterologous 
expression of SLPs. 
In order to co-express Neisserial Slam1 and SLPs in E. coli, two different strategies were tested. 
Firstly we generate E. coli strains where fHbp and Slam1 were co-expressed on different 
plasmids as described in material and methods (7.2.2). E. coli BL21 (DE3) strain was co-
transformed with 2 distinct compatible plasmids carrying fHbp or Slam1, respectively. Schematic 
representation of the plasmid used in this study, is shown in Figure 29.A.  
  
Figure 29 Heterologous expression of Slam1 and fHbp in E. coli. A) Schematic representation of plasmids used 
for fHbp and Slam1 co-expression in E. coli. Plasmids were both carrying LacI repressor gene and have 
compatible origin of replication with different promoter and resistance cassettes. Bacteria transformed with 
both plasmids were growth on LB AGAR plate with different IPTG concentration (0.001 mM, 0.01mM or 0.1mM 
IPTG). After O/N growth at 37°C, total lysate bacteria or fixed bacteria were collected. B) Western blot analysis 
with α-fHbp polyclonal mouse (diluted 1:5000) and α-Slam1 (1:1000) antisera on empty bacteria, bacteria 
expressing only fHbp or co-expressing fHbp and Slam1 were show. C) FACS analysis performed using polyclonal 
α-fHbp mouse (1:1000) polyclonal antisera against the same samples collected analyzed by Western blot to 
check fHbp surface localization. *aspecific band  
A 
B C 
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The resulting strains expressing fHbp in the presence or absence of Slam1 were grown on LB 
agar plates with different IPTG concentrations (final concentration 0.001; 0.01; 0.1 mM IPTG). 
Expression levels of both proteins responded to IPTG induction and the expression of both 
proteins were confirmed by WB analysis of total lysate (Figure 29.B) translocation on the 
surface was examined with FACS analysis (Figure 29.C ).  
In the presence of Slam1 the amount of fHbp in the total extracts strongly increased compared to 
the strain expressing fHbp alone, and this higher fHbp amount was reflected by higher 
detectable fHbp on E. coli surface. fHbp expressed alone was visible by WB in all samples but 
FACS analysis reveals that fHbp was detectable on bacteria surface only at higher IPTG 
concentrations (0.01mM and 0.1mM). However when co-expressed of Slam1, fHbp was 
appreciable on the surface already at the lower IPTG concentration (0.001mM). Furthermore, 
observing fHbp amount on bacteria total lysate, even if fHbp amount is comparable (fHbp+Slam1 
induced with 0,01mM IPTG and fHbp alone induce with 0,1mM IPTG) the presence of Slam1 
results in greater exposure of fHbp on bacteria surface. 
Despite these promising results, the co-expression strategy, in our hands was not applicable to 
liquid culture as bacteria tend to lose plasmid carrying fHbp (data not shown). 
In order to avoid plasmid loss, in a second strategy, we cloned fHbp and Slam1 on the same 
plasmid as described in the material and methods (7.2.2). E. coli BL21 (DE3) was transformed 
with this new construct, and as controls E. coli carrying plasmid expressing fHbp or Slam1 alone 
and the empty pCOLA plasmids (Ø) were also used. (Figure 30.A). BL21 transformed with this 
set of plasmids were plated on LB agar plates with different IPTG concentration (0.001 or 
0.1mM) and after O/N growth at 37°C bacterial total lysate and fixed bacteria were collected 
from all E. coli strains. 
As previously described, fHbp and Slam1 expression was modulated by adding different IPTG 
concentration, and also in this case the presence of Slam1 positively affected fHbp expression 
and surface localization. 
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Western Blot analysis of lysates from bacteria grown on plates indicated only minor differences 
in fHbp amount in cultures in the presences or absence of Slam1 at either IPTG concentration 
(0.001 or 0.1mM), (Figure 30.B). FACS analysis, on the other hand, revealed that fHbp was 
detectable on the surface of both E. coli strains under conditions of 0.1mM IPTG, but when Slam1 
was also present, fHbp surface exposure was more compared to the one expressing fHbp alone 
(Figure 30.C), At the lower IPTG concentration (0.001 mM) fHbp was only detectable on the 
surface in the presence of Slam1. This suggests that when expression levels are lower the role of 
Slam1 in the stable surface localization of the fHbp is more critical. 
  
Figure 30. Heterologous expression of Slam1 and fHbp in E. coli, with new set of constructs.  A) Schematic 
representation of the new set of plasmids used for co-expression. fHbp was cloned in the first multi-cloning 
site, while Slam1 was cloned in to the second multi cloning site. Expression of both proteins was IPTG 
regulated. B) Western blot of bacteria total lysate collected after O/N incubation at 37°C on LB agar plates in 
the presence of different IPTG concentrations (0.01mM and 0.1mM IPTG). Proteins expression was checked by 
Western Blotting using α-fHbp (1:5000) or α-Slam1 (1:1000) mouse polyclonal sera. C) FACS analysis performed 
using polyclonal anti-fHbp mouse polyclonal antisera (1:1000) against the same samples collected analyzed by 
Western blot, was done to control fHbp surface localization. *aspecific band, empty vector ( Ø ) control. 
A 
B C 
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Liquid cultures were set up in order to produce OMVs. Since OMVs are usually released during 
stationary phase; specific growth protocol was set up (7.9.2). Briefly bacteria strains were 
grown in defined liquid media (HTMC) overnight in the presence of IPTG from the beginning of 
the growth inoculating from a pre-culture which had been grown at 37 °C for several hours as 
described in materials and methods.   
Under these conditions we were able to observed clear differences in fHbp surface exposure 
depending on the presence of Slam1. Western blot analysis confirms fHbp and Slam1 expression 
in all constructs (Figure 31.A) and FACS analysis confirm the presence on the surface of fHbp 
only when Slam1 was expressed (Figure 31.B). Cell free supernatants were collected from these 
preparations and OMVs were purified as described in material and methods (7.9.2).  
These findings are someway in contrast to the findings of Fantappiè et al., where expression of 
fHbp and NHBA in E. coli results with their surface localization. In order to understand if we 
could also repeat the results of Fantappie et al., we performed the culturing of our E. coli strains 
as described in the reported article. As such, initially, bacteria were grown until exponential 
phase without IPTG and then protein expression was induced for 3hours. After induction total 
lysate and fixed bacteria were collected (Figure 32).  
  
Figure 31. Slam1 is necessary for fHbp surface localization in certain growth condition. Bacteria were growth 
on plate O/N. Liquid growth on HTMC media was performed after O/Day pre-inoculum. 0.1mM IPTG was 
added in the media at the beginning of the O/N incubation. After 12/14 hours bacteria total lysate for WB 
analysis and fixed bacteria for FACS analysis were collected. A) Western blot analysis stained with α-Slam1 
(1:1000) or α-fHbp (1:5000) polyclonal sera confirmed the expression of both proteins. B) FACS analysis 
performed using polyclonal α-fHbp mouse polyclonal antisera (1:1000) against the same samples collected 
analyzed by Western blot, was done to control fHbp surface localization. *aspecific band. 
 
 
A B 
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Proteins induction was confirmed by WB. Slam1 and fHbp in both conditions (with or without 
Slam1) were visible as reported on WB (Figure 32.A). FACS analysis show only a slight decrease 
in fluoresce intensity when fHbp was expressed alone (Figure 32.B). Therefore under 
conditions of optimal and high protein expression, fHbp can be detected on the surface by FACS 
in the absence of Slam1 co-expression in agreement with the results obtained with plate 
cultures. 
 
 
 
 
  
Figure 32. After three hours induction in liquid culture Slam1 is not required for surface exposure. Bacteria 
were growth on plate O/N. Liquid growth on LB media was then performed. 0.1mM IPTG was added for 3 hours 
to the media when bacteria have reached exponential phase, after that bacteria total lysate for WB analysis and 
fixed bacteria for FACS analysis were collected. A) Western blot analysis stained with α-Slam1 or α-fHbp 
confirmed the expression of both proteins. *aspecific band, empty vector ( Ø ) control. B) FACS analysis 
performed using polyclonal α-fHbp mouse polyclonal antisera against the same samples collected analyzed by 
Western blot, was done to control fHbp surface localization.  
A 
B 
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5.1.2 Slam1 is necessary for NHBA surface translocation in E. coli 
N. meningitidis NHBA was identified as a lipoprotein translocated on bacterial surface by Slam1 
as described before. As for fHbp, NHBA was cloned with or without Slam1 in pCOLA Duet 
plasmid, as described in the material and methods (7.2.2). 
BL21 (DE3) E. coli strain was transformed with the plasmids set. These bacteria strains were 
grown (described in paragraph 7.9.2) in defined liquid media (HTMC) in the presence of IPTG 
from the beginning of the growth, as was done for fHbp. Bacteria total lysate and fixed bacteria 
for FACS analysis were collected.  
Western blot analysis confirmed NHBA expression in bacteria total lysate from both E. coli 
strains, when NHBA was expressed alone and when was co-expressed with Slam1 (Figure 
33.A); interestingly as for fHbp NHBA amount seems to be higher when Slam1 was also 
expressed.  
On the other hand FACS analysis reveal that no NHBA was detectable on the bacteria surface 
when Slam1 was not expressed (Figure 33.B). Curiously bacteria co-expressing Slam1 and 
NHBA show two different populations expressing different levels of NHBA on the surface. 
Cell free supernatants were collected from these preparations and OMVs were purified as 
described in material and methods. 
  
Figure 33 NHBA required Slam1 for surface exposure. Bacteria were growth on plate O/N. Liquid growth on 
HTMC media was performed after O/Day pre-inoculum. 0.1mM IPTG was added in the media at the beginning 
of the O/N incubation. After 12/14 hours bacteria total lysate for WB analysis and fixed bacteria for FACS 
analysis were collected. A) Western blot analysis stained with α- N term NHBA monoclonal antibodies (1:4000) 
confirmed NHBA expression. B) FACS analysis performed using α- N term NHBA monoclonal antibodies (1:800) 
on fixed bacteria, was done to control NHBA surface localization. Empty vector ( Ø ) control 
A B 
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5.2 E. coli OMVs are enriched on Neisserial proteins 
5.2.1 Neisserial fHbp lipoprotein is present in heterologous OMVs preparations at high 
level 
OMV were purified using a detergent-free method from cell-free culture supernatants through 
ultracentrifugation. At electron microscopy analysis by negative staining (Figure 34) indicated 
the resulted vesicles appear round and with comparable size. OMVs integrity was also 
confirmed. 
 
Equal amounts of OMVs with respect to total protein quantities from all preparations were 
loaded onto SDS-PAGE gel and either visualized by Simply BlueTMSafe staining or blotted onto 
nitrocellulose membrane and then the proteins of interest detected using polyclonal mouse sera. 
E. coli OMVs showed similar pattern bands among preparations, furthermore bands at the 
expected molecular weight of fHbp and Slam1 are visible in the SDS-PAGE .  
SDS-Gel page and WB analysis (Figure 35.A .B) both confirmed differences in fHbp amount in 
OMVs depending on Slam1 expression. It is worth noting that OMVs from E. coli co-expressing 
fHbp and Slam1 contain really high amounts of fHbp where it appears as the most abundant 
protein in the OMVs as is shown in SDS Gel page. In order to quantify better the differences in 
the total amount of fHbp between OMVs preparation expressing fHbp alone or co-expressed 
with Slam1, Western Blot with OMVs serial dilutions was performed (Figure 35.C). OMVs with 
fHbp co-expressed with Slam1, results in over 10 times more fHbp than in OMV where fHbp is 
present alone.  
  
Figure 34 Electron microscopy on E. coli OMVs. Negative staining of purified E. coli OMVs expressing fHbp 
alone or with Slam1. OMVs purified from empty control bacteria were also show (Ø). 
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Figure 35 Characterization of E. coli OMVs preparations. A) SDS gel page with 7.5 µg of OMVs loaded stained 
with Simply BlueTMSafe; B) Western blot performed on 1.5 µg (protein content) of OMVs stained with α-fHbp 
polyclonal sera (1:5000) and Slam1 policlonal sera (1:1000); C) Western blot performed on OMVs serial 
dilutions with α-fHbp polyclonal sera (1:5000). 
A B 
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5.2.2 NHBA Neisserial lipoprotein is present in E. coli OMVs 
As for fHbp preparations OMV were purified using a detergent-free method from cell-free 
culture supernatants, collected after O/N growth, through ultracentrifugation  
Equal amounts of OMVs with respect to total protein quantities from all preparations were 
loaded onto SDS-PAGE gel and visualized by Simply BlueTMSafe staining. OMVs preparations 
showed similar pattern bands, and in preparations where proteins were induced, bands at the 
expected molecular weight of NHBA and Slam1 were visible (Figure 36.A). SDS gel Page of 
OMVs confirmed the difference in NHBA amount observed by western blot of bacterial total 
lysate. Even if, expression level of NHBA were not comparable with expression reached by fHbp 
expression with or without Slam1, slight difference between NHBA expressions among 
preparations was observed.  
Western blot on serial dilution of OMVs carrying NHBA alone or with Slam1 was performed 
(Figure 36.B) and shows high number of NHBA dependent bands, probably due to intrinsic 
predisposition of NHBA cleavage [50] (Ø: 1 µg of empty OMVs as control for antibody 
specificity). A part of that, different amount of NHBA among the two preparations was 
appreciable. 
  
Figure 36 Characterization of E coli OMVs preparations. A) SDS gel page with 7.5 µg of OMVs loaded stained 
with Simply BlueTMSafe; B) Western blot performed on serial OMVs serial dilutions with α N-term monoclonal 
antibody (1:4000). 
B A 
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5.3 Neisserial SLPs delivered by heterologous OMVs are able to induce 
coverage against N. meningitidis  
5.3.1 fHbp delivered on heterologous OMVs elicited high functional antibody titers 
CD-1 mice were immunized intra-peritoneally two times with: 2µg or 0.2 μg native E. coli OMVs 
and 1 μg of recombinant fHbp protein variant 1.1 (rfHbp) (Figure 37) to evaluate whether the 
co-expression of Slam1 with meningococcal SLP in the heterologous E. coli background has an 
effect on the immunogenicity of the resulting OMVs.  
 
Elicited antibody titers were evaluated by ELISA analysis using immunized sera of individual 
mice from each group and rfHbp as a coating antigen as described in the material and methods 
(paragraph 7.13) ( Figure 38). 
 
Figure 38 Analysis of sera from mice immunized with E. coli OMVs preparation or recombinant fHbp 
protein. IgG α-fHbp antibody titers elicited measured by ELISA. Each dot represents an individual mouse 
serum while bars indicates the median value within each immunization group. Statistical analysis was 
performed using Kruskal-Wallis multiple comparisons test (ns: not significant; **p<0.0065; ***p<0.0009, 
****p<0.0001). 
Figure 37 Immunization scheme. Upper panel: eight CD-1 mice were immunized intra-peritoneally (IP) two 
times, as indicated. Bottom panel: Bottom panel: representation of the immunization scheme. Amount of 
native E. coli OMVs, adjuvant dose and the site of injection were indicated. (Ø: Empty native OMVs) 
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Formulation of OMVs carrying fHbp, with the exception of 0.2 µg of OMVs carrying fHbp alone, 
elicitates antibody titers which were significantly higher than the negative controls (Ø OMVs and 
Slam1 OMVs) and comparable to the recombinant protein (rfHbp). A trend dose-dependent anti-
fHbp titers from sera immunized with fHbp OMVs preparation was visible, while apparently no 
difference between the two doses of fHbp+Slam1 OMVs preparation were detected.  
Antibody fuctionality was evaluated by serum bactericidal assays with rabbit complement 
(rSBA) as describe in the material and methods (paragraph7.14). Mice sera were tested against 
N. meningitidis H44/76 meningococcal natural strain, normally used as a reference strain for 
fHbp variant 1.1. (Figure 39). 
 
 
Accordingly with ELISA titers, no killing was achieved with sera derived from controls (Ø OMVs 
and Slam1 OMVs); while good functional response was achieved with sera derived from mice 
immunized with the preparation expressing fHbp.  
Titers from 6 out of 8 mice from the immunizations (2 µg and 0.2 µg) of the fHbp+Slam1 OMVs 
preparation are really high, but again no differences were detected between the two doses of 
OMVs. In addition, differently from what emerged from ELISA titers, 2 µg of fHbp OMVs, and 
both doses of fHbp+Slam1 OMVs preparation gave higher bactericidal titers compared to 1µg 
rfHbp v1.1, indicating that fHbp expressed in its natural conformation on OMVs improves the 
functional immune response as compare to the recombinant protein. 
  
Figure 39 Serum bactericidal antibody (SBA) titers against H44/76 meningococcal strain. Dots represent SBA 
titers of individual mouse sera against the defined strain. Statistical analysis was performed using Kruskal-
Wallis multiple comparisons test ( **p<0,0024, ****p<0.0001) 
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5.3.2 NHBA delivered in the lumen or on the surface of E. coli OMVs elicitates different 
functional antibody 
OMVs preparations expressing NHBA variant p3 with or without Slam1 and relative controls 
preparations were included into the immunization scheme as summarized in Figure 40. CD-1 
mice were immunized intra-peritoneally two times with 2 μg OMVs or 1 μg of recombinant 
NHBA (rNHBA) variant p2, formulated with aluminum hydroxide. 
 
 
Elicited antibody titers were evaluated by ELISA assay using rNHBA protein as a coating antigen 
(Figure 41). ELISA revealed that all preparations, including NHBA OMVs, elicited α-NHBA 
antibodies which were specific and significantly higher than negative controls (Ø OMVs and 
Slam1 OMVs). Sera from mice immunized with NHBA+Slam1 OMVs show higher antibodies 
titers in comparison to sera of mice immunized with OMVs with only NHBA expression, and 
show a trend to be higher than mice immunized with 1µg of rNHBA protein. 
Figure 41 Analysis of sera from mice immunized with E. coli OMVs preparation or recombinant NHBA 
protein. IgG α-NHBA antibody titers elicited measured by ELISA. Each dot represents an individual mouse 
serum while bars indicates the median value within each immunization group. Statistical analysis was 
performed using Kruskal-Wallis multiple comparisons test (**p<0.0060; ***p<0.0002) 
Figure 40 Immunization scheme. Upper panel: five CD-1 mice were immunized intra-peritoneally (IP) two 
times, as indicated. Bottom panel: representation of the immunization scheme. Amount of native E. coli 
OMVs, adjuvant dose and the site of injection were indicated. 
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Antibodies efficacy were evaluated with rSBA assay, performed with pooled mice sera, against a 
set of N. meningitidis reference strains, expressing differently NHBA variant p2 (Figure 42.A) or 
single mice sera (Figure 42.B) 
 
Conversely from what we observed with ELISA assay, no bactericidal activity was achieved by 
the sera derived from mice immunized with NHBA OMVs, whereas pooled sera from OMVs 
expressing both NHBA and Slam1 (NHBA+Slam1 OMVs) exhibited higher responses than the 
pooled sera from the group immunizes with 1 µg of recombinant protein. To be notice also that 
E. coli OMVs expressing NHBA variant p3 are able to kill the selected panel of N. meningitidis 
strains expressing the same variant of the rNHBA used in the immunization as control (NHBA 
A 
B 
Figure 42 Serum bactericidal activity (SBA) performed on a panel of strains. A) Pooled mice sera were tested 
against strains naturally expressing NHBA p2 variant (NGH38 and M4497); Over expressing NHBAp2 (5/99 OE 
NHBA p2) or not expressing NHBA (5/99 ΔNHBA). rNHBA variant p2 immunized mice sera were also tested as 
a control. B) Single mice sera were tested against 5/99 OE NHBA p2 reference strain. Dots represent SBA 
titers of individual mouse sera against the defined strain. Statistical analysis was performed using Kruskal-
Wallis multiple comparisons test. Statistical analysis was performed using Kruskal-Wallis multiple 
comparisons test (test:  **p<0,0051). 
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variant p2) and the bactericidal activity is specifically mediate by NHBA since the strain lacking 
NHBA (5/99ΔNHBA) in not killed with none of the sera.  
SBA was performed using single mice sera against selected N. meningitidis strain: 5/99 over 
expressing NHBA strain (5/99 OENHBAp2) (Figure 42. B) confirmed results obtained with 
pooled mice sera. 
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6 Discussion and conclusions  
OMVs have an intrinsic adjuvant effect on the antigens which are delivered. Immunization with 
OMVs purified from a pathogen can result in protection against the homologous bacteria [74, 95, 
131]; but also against heterologous antigens that can be incorporated on the OMVs or combined 
in the same formulation [81, 91, 110]. Antigen localization in OMVs is thought to be important 
for the type of immune response induced [132], and surface localization is generally preferred 
because antigens can be easily engaged and presented by immune cells and stimulate high 
antibody levels [106]. Never the less, previous studies have shown the ability of E. coli OMVs to 
stimulate good immune responses when delivering foreign antigens, in their lumen [107, 108, 
114, 115]. In this work we wanted generally to ask if Slam1 has an impact on immunogenicity of 
SLPs heterologously expressed in E. coli OMVs; and more specifically to exploit the role of Slam1 
in surface localization of meningococcal SLPs in order to compare the immune response elicited 
by OMV delivered heterologous antigens with different localization.  
Two of the main antigens of the multicomponent Bexsero vaccine against group B 
meningococcus included in the formulation as recombinant proteins [128, 129] are surface 
lipoproteins, namely Neisserial Heparin Binding Antigen (NHBA) and factor H binding protein 
(fHbp). And we chose to heterologously express these proteins with and without Slam1 in E. coli. 
Two different groups have recently investigated the heterologous surface localization of N. 
meningitidis fHbp (Hooda et al. and Fantappiè et al.) and NHBA (Fantappiè et al.) and two 
different outcomes emerged. Hooda et al. demonstrated the importance of Slam1 for correct 
fHbp display [59]. On the other hand, Fantappiè and co-workers, proposed the presence of a new 
sub-class of Surface Lipoproteins which is able to reach the bacterial surface even when 
transplanted in a different Gram-negative bacterium, suggesting that no additional translocator 
components are necessary for heterologous lipoproteins surface delivery [130].  
In this study, we generated E. coli strain expressing Nm SLPs with or without Slam1 by using 
expression plasmids, we checked surface translocation of selected SLPs in different growth 
conditions and investigate the differences in the immunogenicity due to the presence of Slam1. 
Our results indicate that Slam1-dependency in surface exposure of the analyzed SLPs depends 
on the growth conditions, and possibly on the extent of the over-expression of the heterologous 
expression levels. In particular when SLPs expression was induced from the beginning of the 
growth, Slam1 was necessary for the surface localization of fHbp and NHBA as Hooda et al. 
described. On the contrary, when protein expression was induced maximally, for three hours, 
only when bacteria have reached exponential phase, no differences were observed in fHbp 
surface localization, similarly to what Fantappiè et al. showed.  
Different hypothesis could be made to explain this phenomenon. E. coli could activate unknown 
mechanisms which allow N. meningitidis SLPs surface display. For example it is possible that the 
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same mechanism involved in the anchoring of RcsF to E. coli outer leaflet of the OM, could have a 
role in this [48, 133, 134]. Also, expression levels reached could, in some way, saturate the 
periplasm and impact on the outer membrane stability/integrity, therefore making fHbp 
detectable from antibodies even if it is attached to the OM but facing the periplasm. Or possibly 
under maximal over-expression conditions, a subset of the cells die and lyse and SLPs re-
associate with the surface of the E. coli cells.  
Nevertheless, from our results it is clear that we can generate E. coli expressing fHbp and NHBA 
with different localization depending on the presence of Slam1 and, assuming that OMVs are a 
representation of the bacterial outer membrane, we can obtain OMVs preparations enriched 
with heterologous lipoproteins either within the lumen or surface exposed. In particular, we 
generated OMVs from E. coli expressing the fHbp and NHBA SLPs either on the surface or not 
depending on the co-expression of Slam1. SLPs expression increases in the presence of Slam1, 
this is particularly evident for fHbp which was 10-fold more and becomes the most abundant 
protein within E. coli OMVs when co-expressed with Slam1. Instead the quantity of NHBA in 
OMVs when co-expressed with Slam1 was at most 2-fold more in the presence of Slam1. It is 
possible that the correct localization of fHbp and to a much lesser extent NHBA, or an additional 
stabilizing function of Slam1 could result in the accumulation of SLPs in the heterologous outer 
membrane. These data are in alignment with the impact of Slam1 on expression of fHbp in 
meningococcus that we described in the previous chapter. Sera from mice immunized with OMV 
preparations expressing SLPs at different levels and with different localization due to Slam1 
presence were analyzed in comparison to sera from mice immunized with the respective 
recombinant proteins. Both OMVs co-expressing fHbp and Slam1 or NHBA and Slam1 were able 
to elicit higher bactericidal titers compared to the preparations expressing SLPs alone or the 
control recombinant proteins. Even if ELISA titers show induction of similar antibody levels, the 
functionality of such antibodies were significantly different. This clearly demonstrates the 
advantage of co-expression of Slam1 on the immunogenicity of heterologously expressed SLPs. 
Importantly no killing was achieved by the sera derived from mice immunized with NHBA OMVs 
preparation. In both cases the presence of Slam1 positively stimulates the production of 
functional α-fHbp or α-NHBA antibodies confirming the necessity of the translocator component 
for the correct localization of the selected SLPs on E. coli surface and the reinforcing the concept 
that surface display is preferred for the generation of functional immune system responses.  
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 Materials and methods 7
7.1 Bioinformatics analysis 
Alignment of the first 50 aminoacid of the predicted list of lipoproteins was performed using the 
Clustal W algorithm incorporated within the Geneious software (Biomatters). 
7.2 Generation N. meningitidis recombinant strains and plasmids for E. coli 
proteins expression 
7.2.1 Construction of N. meningitidis mutants and complemented strains  
All recombinant strains and plasmids used in this study are listed in Table 9, while all the 
oligonucleotides used are listed in Table 8. DNA manipulations were carried out routinely as 
described for standard laboratory methods [135]. Generation of 5/99 recombinant strains (5/99 
ΔNadA ΔNHBA; 5/99 ΔNadA ΔNHBA oeNHBA p2 and 5/99 ΔNadA ΔNHBA ΔfHbp) are described 
in Serruto et al. [50].  
The plasmid pGEMT-UDslam1Kan was constructed to generate the nmb0313 isogenic mutant 
(ΔSlam1 strains). This plasmid contains the Kanamycin resistance gene (KanR) within the 
nmb0313 upstream and downstream flanking regions. Briefly flanking regions of nmb0313 were 
amplified from the MC58 chromosome by PCR using KAPA Hi-Fi polymerase (KAPA Biosystem). 
Upstream (0313UP_F/NMB0313RV UP) and downstream (NMB0313RV DO/0313DO_R) flanking 
were amplified, purified and digested with appropriate restriction enzyme sites and cloned into 
pGEMT plasmid. Kanamycin cassette was cloned as 1,4 kb XbaI fragment into the XbaI site 
between the two flanking regions. This plasmid was used to transform NGH38 and MC58 N. 
meningitidis strains using Kanamycin resistance cassette for selection. Complementation of 
nmb0313 was achieved by insertion of a copy of the nmb0313 in the noncoding region between 
the converging ORF NMB1428 and NMB1429 of Δ0313 strains chromosome (CiSlam1). To do 
this, plasmid pInd0313 was generate by amplifying nmb0313 gene (primers 0313 pC_F/R) from 
chromosome and cloned as AseI/NsiI fragment under the control of the inducible promoter pTac 
and the LacI repressor into pComPInd plasmid [136]. Both NGH38ΔSlam1 and MC58ΔSlam1 
were complemented ex-locus with this construct and Chloramphenicol resistance cassette 
present in the plasmids was used for selection.  
Fusion proteins, with N-terminal portion exchanged between fHbp and NHBA, (N-f and f-N 
fusions) sequences were ordered from Invitrogen and cloned in pCompIND plasmid. Nucleotide 
sequences of N-f fusion (NHBA pC_F/fHbp pC_R) and f-N fusion (fHbp pC_F/NHBA pC_R) were 
amplified by PCR using KAPA Hi-Fi polymerase (KAPA Biosystem). Inserts were cloned as 
NdeI/NsiI in pCompIND vector. This plasmid was used for ex-locus complementation, as 
described above, in MC58 ΔNHBA ΔfHbp background. Truncated NHBA forms were generated by 
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mutagenize each serines (2132mS1 F/R and 2132mS2F/R) in the cleavage site of NHBA already 
cloned in pCompIND vector. This plasmid was used for ex-locus complementation in MC58 
ΔNHBA background.  
The correct nucleotide sequence of each plasmid was confirmed by DNA sequencing. Plasmids 
were linearized and used for the transformation of the N. meningitidis strains. All meningococcal 
transformants were verified both by PCR analysis and Western blot.  
All primers (Table 8) and generated plasmids (Table 9) and transformants (Table 10) are 
reported in the appendix. 
7.2.2 E. coli expression plasmids cloning 
DNA manipulations were carried out routinely as described for standard laboratory methods 
[137].  
For fHbp and Slam1 co-expression two different plasmids, with compatibles origin of 
replications (ORI) and antibiotics resistance cassettes, were used for express singularly Slam1 
and fHbp.  Slam1 sequences were amplified (i0313_F/R) from N. meningitidis MC58 genome by 
PCR using KAPA Hi-FI polymerase (KAPA Biosystem) and cloned as MfeI-XhoI fragment into 
MCS2 pCOLA Duet empty vector. fHbp v1.1 from N. meningitidis MC58 was cloned into 
pCompIND inducible plasmids [136, 138] and used for fHbp expression. BL21 (DE3) E. coli strain 
was transformed with both plasmids together and as negative controls E. coli were transformed 
with pCOMpIND fHbp and pCOLA empty; pCOMpIND empty and pCOLA Slam1 or pCOMpIND 
empty and pCOLA empty. 
To construct E. coli co-expressed fHbp or NHBA with Slam1 on the same vector pet Duet plasmid 
family were used. Sequences were amplified from N. meningitidis MC58 genome by PCR using 
KAPA Hi-FI polymerase (KAPA Biosystem). fHbp (ifHbp_MCS1_F/R) and NHBA 
(iNHBA_MCS1_F/R) were amplified and inserts were cloned as NcoI/NotI in the Multi Cloning 
site (MCS1) of pCOLA empty vector, for single expression; or Slam1 pCOLA plasmid for proteins 
co-expression. Correct nucleotide sequence of each plasmid was confirmed by DNA sequencing.  
All plasmids generated and primers used in this study were summarized in the appendix section 
in the Table 9 and Table 8 respectively.  
7.3 Bacterial strains and culture conditions 
7.3.1 N. meningitidis growth conditions  
Neisseria meningitidis (Nm) serogroup B strains (MC58, NHGH38 and its isogenic derivatives) 
and Escherichia coli (Ec) (DH5α) strains used in this study are listed in Table 10.  
N. meningitidis strains were routinely grown on Gonococcus (GC) agar (Difco) plates 
supplemented with Kellogg's supplement I at 37°C, 5% CO2 overnight. When required, 
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Kanamycin or Chloramphenicol was added on the plates (final concentration of 150µg/mL and 
5µg/mL respectively). Liquid cultures were grown under the same conditions in GC with 
Kellogg’s supplement I. Colonies from overnight growth were used to inoculate 7 ml cultures at 
∼0.05 OD600/mL. The cultures were incubated at 37°C with shaking until exponential phase 
(∼0.5 OD600/mL). When required isopropyl β-D-1-thiogalactopyranoside (IPTG) (Sigma) was 
added to culture medium at the indicated final concentrations. Strains were stocked in GC 
medium with 15% glycerol and were stored at −80°C.  
7.3.2 E. coli growth conditions  
The list of bacteria strains used in this work is reported in the table of strains (Table 10). E. coli 
DH5α [139] and BL21 (DE3) were used for cloning and proteins expression respectively. 
Plasmids cloning were performed with DH5α E. coli strain; bacteria were cultured on Luria 
Bertani (LB) medium in the presence of Kanamycin (final concentration 50µg/mL) or Ampicillin 
(final concentration 100µg/mL) for selection.  
BL21 (DE3) E. coli strains were cultured on LB agar plate or LB broth at 37 °C, in the presence of 
Kanamycin and/or Ampicillin to achieved final concentration of 50 µg/mL or 100 µg/mL 
respectively. When required, isopropylβ-D-1-thiogalactopyranoside (IPTG) (Sigma) at different 
final concentrations (0.001; 0.01; 0.1 mM) was also added. 
7.4 Expression of Slam1 recombinant protein for Slam1 anti-sera 
production 
The gene fragment encoding Slam1 (nmb0313), corresponding to residues 32-488, was 
amplified by PCR from N. meningitidis MC58 genomic DNA using primers (i313His_F/R) listed in 
the table of primers (Table 8). PCR fragment was cloned into the pET21 vector using the PIPE 
method [140] to obtain a protein lacking the signal peptide and carrying a 6X His-tag at the C-
terminus. Protein expression was performed in E. coli BL21(DE3) cells, by using EnPresso B 
growth systems (BioSilta, Cambridgeshire, United Kingdom) supplemented with 100 μg/ml 
ampicillin. Bacteria were grown at 30°C for 12 h, and recombinant protein expression was then 
induced by the addition of 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 25°C for other 
24 hours. Bacteria were harvested by centrifugation at 4000rpm for 20 minutes at 4°C and 
lysated by sonication. Protein was extracted from the insoluble fraction with Tris HCl 20mM, 
NaCl 300mM, Urea 8M, pH8 and then purified by immobilized metal ion affinity chromatography 
(IMAC) using HiTRAP (GE Healthcare Life Sciences) and eluted in PBS dilutions in Tris HCl 
20mM, pH8.  
67 
 
5 CDI Female 6-8 weeks old received 20 µg of purified recombinant Slam1 protein adjuvanted 
with 3 mg/ml aluminum hydroxide, for three immunizations intra-peritoneal, with a 3 weeks 
interval. Sera were collected after 49 days at bleed out. 
7.5 Bacteria total lysate preparation. 
N. meningitidis or E. coli colonies from overnight plate cultures were re-suspended in proper 
media to ∼0.5 OD600/mL. One milliliter of the suspension was centrifuged for 5 min at 15000 × g 
and the pellet re-suspended in 100 μl in 2X SDS-PAGE loading buffer (50 mM Tris Cl [pH 6.8], 
2.5% (w/v) SDS, 0.1% (w/v) bromophenol blue, 10% (v/v) glycerol, 5% (v/v) β-
mercaptoethanol, 50 mM dithiothreitol [DTT]) [141]. For liquid culture, 1 ml of each sample was 
collected and the concentration normalized in 2x SDS-PAGE loading buffer respect to the relative 
optical density at 600 nm. 
7.6 Polyacrylamide gel electrophoresis and Western blotting 
Protein extracts were separated by SDS-PAGE on NuPAGE® Novex® 4-12% Bis-Tris Protein 
Gels in MES 1X (Life Technologies) and transferred onto nitrocellulose membrane using an iBlot 
Dry Blotting System (Invitrogen). Membranes were blocked for 1 hour at room temperature 
with PBS with 0.05% (v/v) Tween 20 (Sigma) and 10% (w/v) powdered milk (Sigma) and then 
incubated for 60 min at room temperature with the specific primary antibodies diluted in PBS + 
0.05% (v/v) Tween 20 (Sigma) and 3% (w/v) powdered milk (Sigma). A horseradish 
peroxidase-conjugated anti-mouse IgG antibody were diluted (1:5000) in PBS + 0.05% (v/v) 
Tween 20 (Sigma) and 3% (w/v) powdered milk (Sigma) and the Western Lightning ECL (Perkin 
Elmer) were used according to the manufacturer’s instructions. Antibodies dilutions used were 
specified in the Table 7. 
7.7 Fluorescence Activate Cell Sorting (FACS) analysis  
Strains were growth (plate or liquid) as described in paragraph 7.3 and OD600 0.05 bacteria, for 
each antibodies staining, were collected by centrifugation (10000 × g for 5 min). Pelleted 
bacteria were fixed by 1h incubation at room temperature with PBS containing 0.5% (v/v) 
formaldehyde (Sigma). Fixed bacteria are then suspended in PBS 1%BSA and 10 µl of 
preparation is plated on GC agar plate and incubated O/N at 37°C to check inactivation (for 
menigococcal bacteria) or LB (for E. coli). Inactivated bacteria are then incubated for 1 h at room 
temperature with secondary antibody alone, mouse monoclonal antibodies or mouse polyclonal 
sera diluted to specific concentrations indicated in the Table 7 in PBS containing 1% (w/v) BSA. 
Subsequently cells were incubated for 1 h at room temperature with a secondary rabbit anti-
mouse immunoglobulin G (whole molecule) FITC-conjugated (Sigma). After a final washing step, 
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cells were re-suspended in 200 μl of PBS. All data were collected using a BD FACS CANTO II (BD 
Bioscience) by acquiring 10,000 events, and data were analyzed using the Flow-Jo software 
(v.8.6, TreeStar Inc.).  
 
7.8 Quantitative real-time PCR (qRT-PCR) experiments 
Bacterial cultures were grown in 7 ml of liquid medium to until exponential phase. Three ml of 
the culture were then poured onto 3 ml of frozen medium to immediately chill the culture and 
stop transcriptional changes. Cells were then harvested by centrifugation at 3400 × g for 10 min. 
Total RNA was isolated using an RNeasy Mini kit (Qiagen) as described by the manufacturer. A 
second step of DNase treatment was performed using RQ1 RNase-free DNase (Promega), for one 
hour at 37°C and purified with the RNeasy Mini kit. RNA was quantified using a Nanodrop 1000 
spectrophotometer and its overall quality was assessed by running samples on a 1% agarose gel. 
2 μg of total RNAs were reverse-transcribed using random hexamer primers and SuperScript® 
II RT (ThermoFisher), following manufacturer’s instructions. As controls, all RNA samples were 
also incubated without reverse transcriptase.  
Quantitative real time-PCR was performed in triplicate per sample in a 25 μl reaction volumes 
using Platinum® SYBR® Green qPCR SuperMix-UDG with Rox (ThermoFisher) according to the 
manufacturer’s instructions and containing 2.5 ng of cDNA, and 0.4 μM of gene-specific primers 
(See Table 8). Amplification and detection of specific products were performed with a Mx3000P 
Real-Time PCR system (Stratagene) using the following procedure: 95ºC for 10 min, followed by 
40 cycles of 95ºC for 30 s, 55ºC for 30 s and 72ºC for 30 s then ending with a dissociation curve 
analysis. The 16S RNA gene was used as the endogenous reference control and the relative 
transcript change was determined using the 2-ΔΔCt relative quantification method [142]. 
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7.9 OMVs purification  
7.9.1 Isolation of native N. meningitidis Outer Membrane Vesicles (OMVs) 
The nOMV vaccines were prepared growing NGH38 and derivative strains in MCDMI -
Meningitidis Chemical Define Medium I- medium. The N. meningitidis strains were first pre-
inoculated into 7 mL of MCDMI at an OD600 ranging from 0.15-0.2 and incubated at 37°C at 180 
rpm until mid-exponential phase (=0.8-0.9 OD). Due to the stable nature of the chromosomal 
integration, no antibiotics were added to the growth medium. The mid-exponential pre- cultures 
were inoculated into 50 mL medium in 250 mL baffled flasks and grown over night (16-18 h) 
until late stationary phase at 37°C and 180 rpm. After Overnight growth total lysate for Western 
Blot analysis and fixed bacteria for FACS analysis were collected. Bacterial cells were pelleted by 
centrifugation for 30 min at 5000 × g and 4°C and supernatants filtered (pore size 0.22 μm, 
millipore). nOMVs were collected from cell free supernatants by high speed centrifugation, 2 
hours at 175,000 × g, 4°C. An additional washing step with 1X PBS was performed. OMVs pellets 
were re-suspended in 50-200 μl of 1X PBS and filtered with 0,22µm filter (millipore). OMV were 
quantified through the Lowry assay (DC Protein Assay, BioRad) for total protein content 
following the manufacturer’s instructions. 
 
Table 5 Growth defined media MCDMI recipe 
MCDMI 
Component Final concentration 
 
(g/L) (mMol) 
Soy peptone (BBL Phytone)* 15 NA 
Sodium chloride 5.8 99.2 
Potassium sulphate 1 5.7 
Potassium phosphate dibasic 4 23.0 
L-glutamic acid 5 34.0 
L-arginine 0.3 1.7 
L-serine 0.5 4.8 
L-cysteine 0.25 1.9 
Magnesium chloride hexahydrate 0.41 2.0 
Calcium chloride ** 0.021 0.189 
Ferric citrate *** 0.002 0.008 
Sodium DL-lactate 7.5 66.9 
Glycerol **** 5 NA 
pH 7.2 
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7.9.2 Isolation of native E. coli Outer Membrane Vesicles (OMVs) 
BL21(DE3) strains were pre-cultured over-day in 7 ml of LB medium supplemented with of 
Kanamycin final concentration 50μg/ml. Cultures were diluted 1:100 in 50 ml of HTMC liquid 
medium with Kanamycin 50µg/mL and IPTG at the properly final  concentrations (specified for 
each experiment) and incubated overnight (14-16 h)  at 30°C, 5% CO2, 160 rpm. After Overnight 
growth total lysate for Western Blot analysis and fixed bacteria for FACS analysis were collected. 
Bacterial cells were pelleted by centrifugation for 30 min at 5000 × g and 4°C and supernatants 
filtered (pore size 0.22 μm, millipore). nOMVs were collected from cell free supernatants by high 
speed centrifugation, 2 hours at 175,000 × g, 4°C. An additional washing step with 1X PBS was 
performed. nOMV pellets were re-suspended in 50-200 μl of 1X PBS and filtered with 0,22µm 
filter (millipore). OMV were quantified through the Lowry assay (DC Protein Assay, BioRad) for 
total protein content following the manufacturer’s instructions. 
Table 6 Growth defined media HTMC recipe 
HTMC 
Component g/L 
Glicerol  15 
Yeast Extract(polvere)  30 
MgSO4  ּ  7H2O   0,5 
K2HPO4    20 
KH2PO4      5 
*pH 7.35 with KOH 1M 
  
7.10  Negative Stain Electron microscopy  
OMVs were fixed using 4% PFA in PBS. Droplets of sample suspensions (10 µl) were placed on 
formvar-carbon coated grids and allowed to adsorb for 60 sec. Excess liquid was removed gently 
touching the filter paper. The adsorbed specimen was then processed for negative-staining, by 
first washing the specimen grid on a drop of negative stain (2% uranyl acetate in distilled 
water), blotting and repeating this step once more, this time leaving the specimen grid for 60 sec 
on a new drop of negative stain solution. Samples were observed at a JEOL 1200 EX II electron 
microscope. Micrographs were acquired by the Olympus SIS VELETA CCD camera equipped the 
iTEM software. 
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7.11  Ethical statement  
Animals were housed in the GSK Vaccines Animal Facility and experiments were conducted in 
compliance with the ARRIVE guidelines, the current Italian legislation (Legislative Decree 
116/92), and with the GSK Animal Welfare Policy and Standards. 
All animal experiments were performed in compliance with the approval of the local Animal 
Welfare Body (AWB2015-01). 
7.12 Mice immunization 
Groups of 8 or 5 mice between 6- to 8-week old female CD-1 mice (Charles River) were 
immunized intra-peritoneally (IP).  
For each injection, the mice received a total dose of 2.5, 2 or 0.2 μg of OMV or 1 μg of 
recombinant proteins as described for each specific experiment in the result paragraphs. The 
OMV or the recombinant protein vaccines were absorbed with aluminum hydroxide (Alum, 3 
mg/ml) and administered in two doses at day 1, 21. Blood was taken at day 0; for further 
analysis and bleed out was performed on day 34. The experiment complied with the relevant 
guidelines of Italy and the institutional policies of GSK Vaccines 
7.13 ELISA 
Serum antibody titers against fHbp or NHBA were measured by ELISA. Microtitter plates were 
coated overnight at 4°C with 0.015 μM of purified recombinant proteins (rfHbp v1.1 or rNHBA 
p2) and incubated overnight at 4°C. Afterwards saturation buffer (2.7% polyvinylpyrrolidone 10 
in water) was added to each well and plates incubated for 2 hours at 37°C. Each wells were, 
then, incubated with the single mice sera followed by alkaline phosphatase-conjugated anti-
mouse antibodies diluted 1:2000 in dilution buffer (1% BSA, 0.05% Tween-20, in PBS 0.074M). 
Each steps were followed by three washing steps with the washing buffer (0.05%Tween20,in 
PBS 0.074M). In the end p-nitrophenyl phosphate was added and optical density was analyzed 
using a plate reader at a dual wavelength of 405/620-630 nm. Antibody titers were quantified 
via interpolation against a reference standard curve.  
7.14 Serum Bactericidal Activity (SBA) analysis 
Serum bactericidal activity against N. meningitidis strains was evaluated as previously described 
[143] with pooled baby rabbit serum (Cedarlane) used as the complement source (rSBA). 
Bacteria were grown at 37°C with shaking until early exponential phase (OD600 of ∼0.25) in 
Mueller Hinton broth (MH), plus 0.25% (w/v) glucose, when required 1mM of isopropyl β-D-1-
thiogalactopyranoside (IPTG) (Sigma) was added. Bacteria are then diluted in Dulbecco’s saline 
phosphate buffer (Sigma) with 0.1% (w/v) glucose and 1% (w/v) BSA (Bovine Serum Albumin) 
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to approximately 105 CFU/ml. The incubation with 25% of baby rabbit complement with or 
without polyclonal mouse sera at different dilutions was performed at 37°C with shaking, for 60 
min.  
Serum bactericidal titers were defined as the serum dilution resulting in a at least 50% decrease 
in the CFU/ml of bacteria after 60 min of incubation with the reaction mixture, compared to the 
control CFU/ml at time zero. 
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 Appendix 8
 
Table 7 List of the antibodies and respective working dilutions 
 
Table of antibodies 
  N. meningitidis  E.coli   
Antibodies WB dilution FACS dilution 
WB 
dilution 
FACS 
dilution 
α-NHBA polyclonal serum 1: 2000 1: 800 / / 
α-Mip polyclonal serum 1: 1000 1: 100 / / 
α-fHbp polyclonal serum 1: 5000 1: 1000 1: 5000 1: 1000 
α-NHBA Nterm monoclonal Ab / / 1: 4000 1: 800 
α-Slam1 polyclonal serum 1: 1000 / 1: 1000 / 
α-mouse-FITC / 1:1000 / 1:1000 
α-mouse-HRP 1:2000 / 1:5000 / 
74 
 
Table 8: Table of primers.  
Restriction sites are underlined when present 
Table of primers 
Primer Name Restriction site Sequence Application 
N. menigitidis 
0313UP_F XmaI GagatctagaGCCGGcattcgggcaaaaacc Slam1 KO_Up flanking 
0313DO_R   XhoI gtgtctcgagCTTTTCGCCGATACGGTTTG Slam1 KO_Do flanking 
NMB0313_RV_UP    XbaI AACAGCAACCCGGGTATCAATCGGCGGAT Slam1 KO_Up flanking 
NMB0313_FW_DO       XbaI CCGATTGATACCCGGGTTGCTGTTCCTTTTCG Slam1 KO_Do flanking 
0313 pC_F NdeI Gtgtattaatatggttattttttatttttgtg Amplification Slam1 
0313 pC_R NsI Gtgtatgcattcagaacgttttattaaactc Amplification Slam1 
NHBA pC_F NdeI atatcatatgTTTAAACGCAGCGTAATCG Amplification NHBA 
NHBA pC_R NsI ATATATGCATTCAATCCTGCTCTTTTTTGC Amplification NHBA 
fHbp pC_F NdeI ATATCATATGAATCGAACTGCCTTCTGC Amplification fHbp 
fHbp pC_R NsI ATATATGCATTTATTGCTTGGCGGCAAG Amplification fHbp 
2132 mS1 R 
 
TTATAAACCTAAACCCACTTGATTTGCGCGATTTAGGCGTT Mutagenesis of serine1 NHBA in vector for NHBA p3 variant ex-locus complelmentation 
2132 mS1 F 
 
AACGCCTAAATCGCGAAATCAAGTGGGTTTAGGTTTATAA Mutagenesis of serine1 NHBA in vector for NHBA p3 variant ex-locus complelmentation  
2132mS2 R 
 
TTCTGCACGGTCGAGGCGGTGACTTCCGGCCGAGATGCCGCT Mutagenesis of serine2 NHBA in vector for NHBA p3 variant ex-locus complelmentation  
2132mS2F   AGCGGCATCTCGGCCGGAAGTCACCGCCTCGACCGTGCAGAA Mutagenesis of serine2 NHBA in vector for NHBA p3 variant ex-locus complelmentation  
S3_0313F 
 
GCAAATTTCCAATTCGCTGG Slam1 Sequencing check 
S5_0313R 
 
CGCGGGACAACAATTCG Slam1 Sequencing check 
S_0313F 
 
GCCTGCCGTCATATCGTTG Slam1 Sequencing check 
S_0313R 
 
CAACGATATGACGGCAGGC Slam1 Sequencing check 
pKX-US-F 
 
CCGGCTCGTATGTTGTGTGG sequencing check pGEMt insertion 
pKX-DS-R 
 
CGAAAGGGGGATGTGCTGC sequencing check pGEMt insertion 
Tac2_fw 
 
GCATAATTCGTGTCGCTCAAGG pCOM pInd insertion and sequencing check 
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Primer Name Restriction site Sequence Application 
COM-C-REV 
 
ACCGGCATCGGCAACTACAC Ex-locus complementation check 
CM-C-Fwd 
 
CCTCGAGCCGCTGACCGAAGG Ex-locus complementation check 
ComSQ 
 
tttgaaaatgagattgagc pCOM pInd insertion and sequencing check 
kan_int_fwd  
 
ATTATCGAGCTGTATGCGGAGTG Kanamicine insertion check 
kan_int_rev   GCAATCCACATCGGCCAGAT Kanamicine insertion check 
pRTNM16sII.F2 
 
CACACTGGGACTGAGACACG qRT-PCR 16S gene 
pRTNM16sII.R2 
 
CAGCCTTTTCTTCCCTGACA qRT-PCR 16S gene 
pRTfHbpU.F 
 
GGCTTGCCGATGCACTAAC qRT-PCR fhbp gene 
pRTfHbpU.R   GTTTTTTCCGCACCTTGTGC qRT-PCR fhbp gene 
E. coli 
i0313F Mfe1 GCAGATCTCAATTGatggttattttttatttttgtg  Cloning of Slam1 in pCOLA vector MCS2 
i0313R XhoI TTACCAGActcgagtcagaacgttttattaaactc Cloning of Slam1 in pCOLA vector MCS2 
ifHbp_MCS1_F NcoI GGAGATATAccatggTGAATCGAACTGCCTTCTG Cloning of fHbp v1.1 in pCOLA vector MCS1 
ifhbp_MCS1_R NotI AGCATTATgcggccgcTTATTGCTTGGCGGCAAG Cloning of fHbp v1.1 in pCOLA vector MCS1 
iNHBA_MCS1_F NcoI GGAGATATAccatggTCTTTAAACGCAGCGTAATC Cloning of NHBA p3 in pCOLA vector MCS1 
iNHBA_MCS1_R NotI AGCATTATgcggccgcTCAATCCTGCTCTTTTTTGC Cloning of NHBA p3 in pCOLA vector MCS1 
ACYCDuetUP1_FW 
 
GGATCTCGACGCTCTCCCTT universal primer FW MCS1 pCOLADuet-1 
DuetDOWN1_RV 
 
GATTATGCGGCCGTGTACAA universal primer RV MCS1 pCOLADuet-1 
DuetUP2_FW 
 
TTGTACACGGCCGCATAATC universal primer FW MCS2 pCOLADuet-1 
T7 Terminator_RV   GCTAGTTATTGCTCAGCGG universal primer RV MCS2 pCOLADuet-1 
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Table 9 Table of plasmids used in this study 
KanR: Kanamycine resistance; AmpR: Ampicillin resistance; CmR: Chloramphenicol resistance 
Table of plasmids 
NAME Description 
Antibiotic resitance 
cassette 
Reference of 
source 
  N. meningitidis      
pGEM-T E. coli cloning vector  AmpR Promega 
pET21 E. Coli expression vector AmpR 
 
pET_0313 E. Coli expression vector with 0313 (aa 32-488) fro protein purifiaction AmpR This study 
pGEMT-
UDnmb0313Kan  
pGEM-T containing the flanking region of nmb0313 with Kan resistance cassette cloned as 
XmaI fragment between flanking regions 
AmpR, KanR This study 
pComPIND CmR 
Plasmid for allelic replacement at a chromosomal location between ORFs NMB1428 and 
NMB1429 and inducible expression under the control of the PTAC promoter and the lacI 
repressor. Upstream of the cloning site is a Cm resistance cassette 
AmpR, CmR REF [60] 
Pind_0313 
Plasmid for the complementation of nmb0313 in the Com region with an IPTG-inducible tac 
prmoter. In Δnmb0313 background 
AmpR, CmR this study 
Pind_N-f  
Plasmid for the complementation of NHBA-fHbp fusion protein in the Com region with an 
IPTG-inducible tac prmoter. In MC58 ΔNHBA ΔfHbp background 
AmpR, CmR this study 
Pind_f-N 
Plasmid for the complementation of fHbp-NHBA fusion protein in the Com region with an 
IPTG-inducible tac prmoter. In MC58 ΔNHBA ΔfHbp background 
AmpR, CmR this study 
pIND_NHBA S1TGA1 
Plasmid for the complementation of short NHBA truncated form in the Com region with an 
IPTG-inducible tac prmoter in MC58 ΔNHBA background 
AmpR, CmR this study 
pIND_NHBA S2TGA2 
Plasmid for the complementation of long NHBA truncated form in the Com region with an 
IPTG-inducible tac prmoter. In MC58 ΔNHBA background 
AmpR, CmR this study 
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Table of plasmids 
NAME Description 
Antibiotic resitance 
cassette 
Reference of 
source 
  E. Coli     
Empty (Ø) 
pCOLA DUET vector: encodes two multiple cloning sites(MCS). With T7 promoter, COLA replicon from 
ColA, lacI repressor and KanR 
Kanamycin Novagen 
Slam1 Construct to express recombinant N.meningitidis Slam1 protein in MCS2 of pCOLA Duet in E. coli.  Kanamycin This study 
NHBA Construct to express recombinant N.meningitidis NHBA p3 protein in MCS1 of pCOLA Duet in E. coli Kanamycin This study 
fHbp Construct to express recombinant N.meningitidis fHbp v1.1  protein in MCS2 of pCOLA Duet in E. coli.  Kanamycin This study 
NHBA_Slam1 
Construct to co-express recombinant N.meningitidis NHBA p3 and Slam1 proteins in MCS1 and MCS2 
respectively of pCOLA Duet in E. coli. 
Kanamycin This study 
fHbp_Slam1 
Construct to co-express recombinant N. meningitidis fHbp v1.1 and Slam1 proteins in MCS1 and MCS2 
respectively of pCOLA Duet in E. coli. 
Kanamycin This study 
pIND fHbp Plasmid fHbp expression with an IPTG-inducible tac prmoter. Ampicillin, Cloramphenicol   Biagini et al 2016 
 
 
 
 
 
 
78 
 
 
 
 
Table 10 Table of strains 
KanR: Kanamicine resistance, AmpR: Ampicillin resistance, CmR Chloramphenicol resistance 
Table of Strains 
NAME Description 
Antibiotic resitance 
cassette 
Reference of 
source 
N. meningitidis strains 
MC58   Laboratory-adapted N.meningitidis reference strain 
  
MC58 ΔSlam1 Slam1 null mutant of MC58 KanR this study 
MC58 CiSlam1 Complemented Slam1 in ΔSlam1 MC58 background KanR, CmR this study 
MC58ΔNHBA Nhba null mutant of MC58 EryR  Ref 
MC58ΔNHBAΔfHbp Nhba and fHbp null mutants in MC58 EryR  
 
MC58 N-f 
Complemented mutant expressing NHBA-fHbp fusion protein under the control  of IPTG 
inducible promoter.  
EryR, CmR this study 
MC58 f-N 
Complemented mutant expressing fHbp-NHBA fusion protein under the control  of IPTG 
inducible promoter.  
EryR, CmR this study 
MC58 NHBA S1TGA1 
Complemented mutant expressing short NHBA truncated form in the Com region with an 
IPTG-inducible Tac prmoter in MC58 ΔNHBA background 
EryR, CmR this study 
MC58 NHBA S2TGA2 
Complemented mutant expressing long NHBA truncated form in the Com region with an 
IPTG-inducible Tac prmoter in MC58 ΔNHBA background 
EryR, CmR this study 
NGH38 Clinical Isolate 
  
NGH38 ΔSlam1 Slam1 null mutant of NGH38 KanR this study 
NAME Description 
Antibiotic resitance 
cassette 
Reference of 
source 
NGH38 CiSlam1 Complemented Slam1 in ΔSlam1 NGH38 background KanR, CmR this study 
5/99 Clinical Isolate 
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5/99 ΔNadA ΔNHBA NadA and NHBA null mutants in 5/99 strain 
  
5/99 ΔNadA ΔNHBA 
oeNHBA p2 
Complemented NHBA variant p2 under the control of IPTG inducible promoter KanR, EryR, CmR 
 
5/99 ΔNadA ΔNHBA 
ΔfHbp 
NadA,NHBA and fHbp null mutants in 5/99 strain KanR, EryR, CmR 
 
 
E. coli strains 
Escherichia coli DH5-α supE44 hsdR17 recA1 endA1 gyrA96 thi-1 relA1   Life 
Technologies 
Escherichia coli BL21-
DE3 
hsdS gal (λcIts857 ind1 Sam7 nin5 lacUV5-T7 gene 1)  Life 
Technologies 
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